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Transdermal drug delivery system has sought various methods to administer 
biopharmaceuticals with the development of the technologies for the production of 
biopharmaceuticals. Because skin has the intrinsic function to protect the body preventing 
entry of the external species into the body, the controlled removal of the skin barrier 
without losing the protection function is the key to the transdermal administration of 
biopharmaceuticals through the skin. 
In this thesis, two physical methods were studied to overcome the skin barrier in the 
controlled breakage of the skin barrier and to deliver macromolecules-based drugs 
through the skin; (1) polysaccharide dissolving microneedles and (2) micro thermal skin 
ablation. 
The previous generation of microneedles has demonstrated the enhanced skin 
permeability to molecules that cannot penetrate stratum corneum, which is the outmost 
layer of the skin, by breaking it in a micron size. However, many types of microneedles 
have focused on the controlled breakage of stratum corneum so microneedles material 
was selected with the good mechanical properties and the capability of the easy 
processability for the mass production. These criteria for the material limited the 
encapsulation of biopharmaceuticals within microneedles due to the incompatible 
properties of them with sensitive biopharmaceuticals. Thus, polysaccharide dissolving 
microneedles system was designed and developed in this study to encapsulate 
biopharmaceuticals without losing their integrity, to break the skin barrier in a minimized 
size with the mechanically poor material, to release them into skin with the dissolution of 
microneedles, and to deliver human growth hormone into the living hairless rats. 
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The skin ablation methods have been evolved to administer biopharmaceuticals 
because it is a simple method to overcome the skin barrier and deliver drugs. Many of 
them have already shown the effect of the removal of stratum corneum on the skin 
permeability to macromolecules, but they are somewhat subjective for the practical 
application or less controlled for the selective removal of the skin barrier leaving the 
possibility of the deeper skin tissue damage. Thus, micro thermal skin ablation was 
designed and developed to fabricate the device generating the energy impact with the 
basis of arc discharge, to transfer the energy impact on the skin, to remove stratum 
corneum selectively with three-dimensionally controlled manner, and to deliver 






Molecular biology and genetic engineering have been instrumental in revealing the 
role of genes and proteins in human disease; therefore effective delivery of these 
compounds into the body has become a significant requirement for health treatments 1-3 
This type of healthcare has also become the challenge for the pharmaceutical industry 4-6 
to lower the cost of treating human disease and improving human health. However, 
biomolecules-based drugs are very sensitive and the oral delivery route is believed to be 
an impossible pathway for these methods due to the digestive and enzymatic environment 
of the gastrointestinal tract and the first-pass effect at the liver 7, which rapidly degrade 
biomolecules. Thus, most biopharmaceuticals have been administered by a parenteral 
method using hypodermic needle injection through skin to avoid these problems. 
However, many are fearful of needles 8, 9 and treatment by injection requires a visit to the 
hospital or clinic for the administration. In addition, hypodermic needles should be 
disposed of under specific protocols because reuse can be another path for disease 
infection. To resolve these problems, pharmaceutical companies are currently focused on 
the design of biopharmaceutical delivery by non-conventional routes 10-12 such as 
transdermal drug delivery systems. 
The role of the integumentary system which is composed of the skin layers and 
accessory structures is the regulation of interactions between the body and the external 
environment for the purpose of protecting the body and maintaining biological functions. 
The protective function of the integumentary system resides in the outer layer of the skin, 
which prevents entry of noxious chemicals and dangerous microorganism and the 
dehydration of the body by controlling water loss. Therefore, it is generally believed that 
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transdermal administration of drugs is feasible for only low molecular weight and 
moderately lipophilic drugs and that it is almost impossible to deliver high molecular 
weight and hydrophilic biomolecules drugs into the body without using hypodermic 
needles. 
Many scientists have studied these barrier properties of the skin 13-16 and the effect 
of skin disruption 17-22 on the absorption of external molecules into the body. It was 
discovered that the most superficial layer of the skin, the stratum corneum, is the 
important layer for blocking entry into the body. For example, using the tape-stripping 
method to disrupt stratum corneum demonstrated an increased absorption of cortisone 
and nicotinic acid 23. Furthermore, skin disruption with a microenhancer array boosted 
luciferase gene delivery 24 comparable to intramuscular or intradermal needle injection. 
However, these methods are limited due to subjective procedures in application; the 
degree of skin disruption is highly variable and cannot be easily controlled, thus causing 
significant differences in drug delivery amounts and/or adverse side effects. The key 
variable in developing a method for breaking stratum corneum to deliver drugs is 
achieving controlled disruption of the skin without losing protective function and thus 
causing unfavorable side effects. To achieve this, stratum corneum should be removed in 
a minimal size possible to allow drugs to be delivered at therapeutic rates without loss of 
protective function. Thus, the best method for making the small holes in the skin is one of 
the most important criteria for the design of transdermal drug delivery system based on 
the breakage of stratum corneum. In this work, we studied two physical methods to 
enable the transdermal delivery of biopharmaceuticals by controlling the disruption of 
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stratum corneum in micro scale: (1) dissolving microneedles and (2) micro skin ablation 
created by energy impact on the skin. 
Microneedles were originally designed to make small holes in the skin 25,  which 
can be passages for the diffusion of drugs into the body. Microneedles applications 20, 26-31 
have already demonstrated increased permeability of drugs after micro-scale stratum 
corneum breakage. We were motivated to design the fabrication of dissolving 
microneedles made out of material dissolvable in the skin because these microneedles 
dissolve in the skin and releases drugs after insertion. It is almost impossible to create 
biohazardous sharps after usage. Moreover, biotherapeutics can be encapsulated in the 
microneedles, maintaining their integrity for long periods of time due to the limited 
mobility of molecules, while trapped in the solid phase 32.  
To develop the second approach for making a delivery route in the micro-scale, we 
designed a micro skin ablation method based on generation of energy impact, which uses 
a rapid and intense energy transfer onto the skin to remove stratum corneum. The impact 
of thermal energy generated by the arc discharge phenomenon will quickly remove only 
stratum corneum because heat energy does not deeply penetrate into the skin, thus 
avoiding damage to the deeper skin tissue. Therefore, stratum corneum can be selectively 
removed in the micro-scale by guiding the thermal impact on the skin with a masking 
system. 
These methods, dissolving microneedles and micro skin ablation, are expected to 
overcome the skin barrier by breaking or removing stratum corneum in a highly 
controlled manner and thereby deliver various kinds of biopharmaceuticals at therapeutic 
rates, which have not been achieved by traditional transdermal patch applications. We 
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expect these two methods to be a new platform for delivery of biopharmaceuticals that 
may bring better quality of life to patients suffering from diseases treatable with these 
means, for example, daily injection with hypodermic needles or delivery with bulky 




2.1 Transdermal drug delivery system 
2.1.1 Drug delivery 
The pathway for drugs to achieve therapeutic effects comprises distinct phases of 
delivery in the body. The first is administration of the drug into the body which will be 
absorbed into the blood stream through absorption membranes, which serve as the gate 
connected to the circulation system. While the drugs circulate along the blood vessels, 
they can either act on the areas of disease or disappear by excretion and/or by catabolic 
metabolism depending upon the drugs. In addition to technical challenges with the 
administration methods 9, the poor absorption of drug 33, 34, the possible unfavorable side 
effects during the circulation 35, 36, etc. make engineering a drug delivery system to obtain 
the optimized therapeutic effect a challenge. 
Since the biomolecules-based biotherapeutics market has been expanding 2, 3, 5 with 
the development of genetic engineering and proteomics, a number of techniques for 
delivering biotherapeutics 32 have been designed and developed to improve the pathway 
and the efficacy of these drugs. Among these techniques, the development of a 
transdermal drug delivery system has been of interest as one of the alternatives to 
conventional injection methods because (1) skin is the most easily accessible site for drug 
administration, (2) transdermal patches are easy and convenient to use, and (3) they 





2.1.2 The barrier properties of skin 
Transdermal drug delivery systems have been investigated for a long time due to 
the advantages described above. However, the skin is exposed to external environments 
and has become evolved into an efficient barrier to prevent entry of harmful chemicals 
and microorganisms. These barrier properties of the skin result from the histological 
layers: the subcutaneous tissue, the dermis layer, and the epidermis layer as shown in 




(a)                                                                      (b) 
 
Figure 2.1 Schematic illustrations of (a) skin and (b) stratum corneum and viable 
epidermis layer. 37, 38 
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The skin consists of two main parts; the outermost layer, epidermis, and the inner 
connective tissue layer, dermis, as shown in Figure 2.1. The dermis layer is 3-5 mm thick 
and the major component of skin. It is composed of mostly collagen fibrous protein 
providing the mechanical properties of skin. The vascular structures, such as blood or 
lymphatic vessels, nerve endings, and various glands, are in this layer to perform 
nutrient/waste exchange, create sensation, regulate body temperature controlling, and so 
forth 37, 39. From the standpoint of transdermal drug delivery, the vasculature elements in 
the dermis layer are the absorption sink causing the concentration gradient of drug 
diffusion from the exterior into skin and are the driving force for drug permeation. 
The epidermis layer creates the barrier function against transdermal drug delivery. 
It has complex multiple layers of cells in the differentiation processes with the changes of 
structure and the lipid content of skin 40-42. While cells in the lower layers of epidermis, 
the viable epidermis, contain typical organelles like mitochondria, the outermost 
epidermis layer, the stratum corneum, is a horny layer with approximately 10-15 μm 
thickness and composed of dead cells, which are the final product of the differentiation 
process. A typical horny cell has an amorphous structure, created by dead keratinized 
cells with approximately 30-40 µm of diameter encompassed by multiple lipid bilayers. 
This envelope structure, in which keratinized cell and lipids are continuously overlapped 
with each other, is shown in Figure 2.2. Because of this ‘brick and mortar‘ structure of 
stratum corneum 41, 43, stratum corneum is the key layer of the skin barrier for regulating 
the flux of molecules from the inside to the outside of the body and vice versa. Due to the 
stratum corneum barrier, only small molecular weight and moderately lipophilic drugs 
are able to diffuse through the skin at a therapeutic rate 44, 45. Consequently, various 
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transdermal methods 46, 47 have been designed for enhanced transdermal delivery of 
hydrophilic or large molecular weight drugs by modulating the barrier properties of 





Figure 2.2 The surface of the overlapped structure of stratum corneum; Images (a) 
by phase contrast 49 and (b) by scanning electron microscopy. 
 
 
2.2 Transdermal drug delivery system with patches 
Historically, a primitive type of transdermal drug patch was used in the form of a 
medicated plaster in China several hundred years ago 49. This prototype of a transdermal 
drug patch (Figure 2.3) simply contained herb extracts composed of small molecules such 
as menthol and methyl salicylate used to soothe inflammation in muscle or to help 
healing of bone fractures by inducing a local analgesic effect. 
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While the barrier properties of skin have been a subject of scientific debate since 
the early 1900’s, it was shown that these properties reside in stratum corneum 50-52 and 
drugs can or cannot permeate stratum corneum depending on their water/oil partition 
coefficient 16, 43, 53 around 1950’s. These scientific findings triggered development of 
transdermal drug delivery systems for systemic therapy. In early 1970’s, the first 
transdermal drug delivery system for 3 days of systemic effect of scopolamine against 
motion sickness 47, Transderm-Scop® was developed by Alza and approved for the USA 
market in 1979. Since then, various types of transdermal drug patches have been 




                                (a)                                                                          (b) 
Figure 2.3 Cross-sectional view (a) of the medicated plaster (b) available over the 
counter (OTC) currently (from www. itmonline.org/jintu). 
 
 
For patch types of drug formulations, it has been suggested that transdermal 
administration for systemic effects might be limited to small and moderately lipophilic 
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drugs because patches are based on the passive diffusion of drugs from the reservoir of a 
patch to skin. Thus, an active transdermal drug delivery system has been sought to deliver 
hydrophilic or large size drugs which are biotherapeutics that cannot permeate through 
intact stratum corneum 54, 55. These active delivery systems have utilized an integrity 
change of stratum corneum or the physical removal and breakage of stratum corneum to 
increase the permeability of the skin. 
 To create an integrity change in stratum corneum, chemical treatment of the skin 
surface or the use of energy application was studied such as chemical enhancement 56, 57 
with various chemicals, sonophoresis 22, 58 with ultrasound, and iontophoresis 18, 59 or 
electroporation 60, 61 with electrical energy. For the removal or breakage of stratum 
corneum, minimally invasive methods were designed, such as the jet injector 62, 63, 
microneedle 20, 27, 28, 31, and skin ablation treatment 19, 21, 64. 
Chemical enhancement for altering stratum corneum was the early approach and 
has been long studied 57 for almost 50 years using various chemicals such as:  
dimethylsulfoxide, azone, pyrrolidone, alcohol, surfactant, and terpenes. The potential 
mechanisms of these enhancers 39 are (1) to act on intracellular keratin and modify its 
conformation to cause swelling of stratum corneum, (2) to affect the desmosomes 
connecting corneocytes, (3) to modify lipid domains surpassing corneocytes, and (4) to 
alter the solvent nature of the stratum corneum. However, the use of chemical enhancers 
has been limited due to skin irritation and the inability to deliver large size drugs. 
Recently, the small peptide identified via phase display could be an enhancer as the co-
administration of the short synthetic peptide and target protein drug was reported with the 
facilitated delivery of the protein drug 65, suggesting that the synthetic peptide creates a 
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transient pathway in the skin to enable transdermal delivery of macromolecular drugs for 
the systemic circulation.  
 
Table 2.1 The classification of rate-controlling transdermal drug delivery systems 49. 
Polymer membrane permeation-controlled system 
• Transderm-Scop® (Scopolamine) 
• Transderm-Nitro® (Nitroglycerin) 
• Catapres-TTS® (Clonidine) 
• Estraderm® (Estradiol) 
 
Adhesive polymer dispersion system 
• Deponit® (Nitroglycerin) 
• Frandol® (Isosorbide dinitrate) 
• Minitran® (Nitroglycerin) 
• Nitro-Dur II® (Nitroglycerin) 
 
Nonadhesive polymer dispersion system 
• Nitro-Dur® (Nitroglycerin) 
• NTS® (Nitroglycerin) 
Microreservoir dissolution-controlled system 






Sonophoresis uses ultrasonic energy to increase the permeation of drugs through 
skin. Although the mechanism of enhanced drug flux by ultrasound has not been fully 
elucidated yet, it has been suggested that sonophoresis has promoting effects for both 
hydrophilic and lipophilic drug delivery. The potential mechanisms of sonophoresis are 
(1) thermal effects causing the increase of molecular diffusivity or fluidity of stratum 
corneum lipids 66, (2) radiation pressure related to the force driving molecules through 
membrane 67, 68, (3) cavitational activity inducing the perturbation of stratum corneum 
lipids 69, 70, and (4) microstreaming by the removal of the unstirred water layer 71. 
Encapsulations systems, Inc. designed an active transdermal drug delivery system 
using ultrasound in conjunction with an insulin patch operated by a programmable 
controller as shown in Figure 2.4 (a). This is designed to deliver both a basal and bolus 
dose of insulin to both Type-1 and Type-2 diabetics. Currently, this device is in Phase-2 
clinical trials and is not yet approved for human use by the FDA. As another example, 
SonoPrep® marketed by Echo Therapeutics (Figure 2.4 (b)) was invented by 
Massachusetts Institute of Technology and was FDA-approved for increasing local 
dermal anesthesia effects with lidocaine. The delivery of a high molecular weight drug 
such as insulin or vaccine with SonoPrep® will be investigated in the future. 
Iontophoresis uses an electrical gradient for the transport of charged drugs like 
peptides or small proteins. Drugs with either a positive or negative charge are dissolved 
in an electrolyte solution, then the drug is repelled from the same polarity electrode and 
attracted to the opposite polarity electrode, thus driving drug into the skin. Two primary 
mechanisms explaining iontophoresis 39, 72 are electromigration and the disruption of skin 




                        
                             (a)                                                                      (b) 
 
Figure 2.4 (a) Transdermal delivery with a programmable ultrasound device, U-
strip®. (Revised images from www.encsys.com) and (b) the SonoPrep® transdermal 




Iontocaine® produced by IOMED, Inc. was FDA approved in May 1996 as the first 
drug (lidocaine) combined with device, in which drug is transferred by an iontophoresis 
controlling device, Numby®  as shown in Figure 2.5. An integrated lidocaine device, 
Lidosite® (Figure 2.6 (a)) was desgined by Vyteris as the first FDA-approved pre-filled 
active anesthetic patch. The iontophoresis of analgesics has been studied for a long time 
73, 74 and fentanyl iontophoretic transdermal system, IONSYS™ produced by Alza Corp. 
was FDA approved in May 2006 (Figure 2.6 (b)). This is a more effective treatment for 
acute pain than passive transdermal patch and provides patients with an on-demand dose 
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of fentanyl. The use of iontophoresis for transdermal delivery of large molecules like 








            
                                 (a)                                                                      (b) 
 
Figure 2.6 (a) Lidosite®, the drug-device integrated iontophoresis system 




Electroporation applies a relatively higher voltage (~100 V) pulse to skin than 
iontophoresis does, but the electric field lasts for a shorter time, usually, 10 µs –10 ms. 
The increased flux of hydrophilic drugs by electroporation is believed to occur by the 
creation of aqueous pathways within stratum corneum 60, 78, 79 or thermal effects of locally 
heated stratum corneum 80, 81. However, the efficiency of electroporation in a single 
bilayer such as cell membranes or microbial membranes is higher than with stratum 
corneum, which containes multiple lipid bilayers in human skin. Thus, most 
electroporation devices are based on invasive needles inserted into dermis or epidermis 
for administration of large-size molecule therapeutics, allowing the intracellular delivery 
to cells in the skin. 
 
2.3 Transdermal drug delivery by the breakage of stratum corneum 
Microneedles were conceptualized in the early 1970’s 25 as a simple idea to 
enhance the skin permeability of hydrophilic and large size molecules therapeutics by 
breaking the skin barrier layer physically. Since the first generation of microneedles was 
fabricated out of silicon 20 using micro-electro mechanical systems (MEMS) in 1998 as 
shown in Figure 2.8, various types of microneedles have been designed and evolved with 
improved features; such as solid metal microneedles 27, hollow metal microneedles 31, 
hollow glass microneedles 82, solid biodegradable polymer 28, and so forth. These 
microneedles enabled various types of transdermal drug delivery 26. Transdermal drug 
delivery with microneedles has been extensively investigated with various drugs 83, 84, 
most of which have hydrophilic properties that are not applicable to passive diffusion-











Figure 2.7 Silicon microneedles fabricated using etching techniques 20 
 
Alza Corp. designed the drug coated microprojection array system, Macroflux® as 
shown in Figure 2.8. They fabricated a titanium microprojection array which is inserted 
with coated drug into skin. Zosano Pharma™, Inc. developed a parathyroid hormone 
(PTH) transdermal delivery system with Macroflux® technology for osteoporosis and 
Phase II clinical trials have been complted. 
For hollow microneedle applications, Nanopass Technologies LTD developed 
MicronJet, an intradermal system for proteins and vaccines requiring minimal expertise 
for administration. As shown in Figure 2.9, the device consists of MicroPyramids made 
of pure silicon crystals which are mounted on a standard syringe for the replacement of a 
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conventional hypodermic needle. Currently, two pilot clinical studies have been 




Figure 2.8 Transdermal drug delivery with Macroflux® technology using drug 








Recently, 3M has developed two types of microstructured transdermal systems 
(MTS): solid microneedles for drug coating (sMTS) and hollow microneedles for liquid 
drug formulation (hMTS) as shown in Figure 2.10. They performed pre-clinical study 85 
of human growth hormone and Naloxone for macromolecules and small hydrophilic 





Figure 2.10 Microstructured transdermal system: solid type (left) and hollow type 
(right) (Revised images from www.3m.com). 
 
 
Hypodermic jet injection was patented in the 1950’s 86 and has been developed to 
accelerate drug penetration of skin as shown in Figure 2.11. The early generation of jet 
injection focused only on delivery of drugs into skin such as mass vaccination in the 
military and it caused problems like bruising or bleeding 87. Due to low patient 
compliance with the painful administration of this technique, jet injection system needs to 
be engineered in such a manner to ensure that it is more patient-friendly and convenient 
to use. Currently, many companies are developing this type of system for insulin, growth 
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hormone, vaccine, and so forth 87. Anesiva designed Zingo™ to deliver lidocaine as a 
topical anesthetic and it was FDA approved in 2007. Antares Pharma has developed a 









2.4 Transdermal drug delivery by removal of stratum corneum 
While microneedles are used to break stratum corneum, another approach for 
overcoming the barrier properties of skin is to remove stratum corneum in a controlled 
manner. The enhanced flux and therapeutic effects of hydrophilic or large size drugs after 
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removal of stratum corneum have been demonstrated by various methods using 
mechanical disruption like tape-stripping 88, 89 or the microenhancer array (MEA, BD 
technology) and the more controlled methods 24 using additional energy, such as laser 
assisted drug delivery by Norwood Abbey 90, thermal ablation by Altea Therapeutics 91, 
and radio-frequency ablation by TransPharma Medical 92, 93. 
The tape-stripping method is a simple way to remove stratum corneum, but is a 
subjective method meaning that the stratum corneum ablation cannot be controlled 
consistently and thus, its effect on the skin permeability of a drug will have significant 
variability. To achieve more controlled skin ablation, BD Technology designed a 
microenhancer array (MEA) system (Figure 2.12), the shape of which is similar to the 
structure of microneedles. The compnay has demonstrated the effect of the MEA system 
on transdermal vaccine delivery 24; however, the technology using the MEA system is not 





Figure 2.12 Microenhancer array (MEA) fabricated by BD technology for the skin 
abrasion (Revised image from www.bd.com). The inset is a SEM image of MEA. 
21 
 
Skin ablation technology requires highly controlled depth of ablation to prevent 
damage of deeper skin tissue. To achieve this, most energy applications for ablation 
should be applied onto the skin for short periods of time; therefore skin ablation using 
laser technologies 19, 64 has been investigated due to the property of laser energy enabling 
rapid energy transfer to skin. Norwood Abbey developed a portable skin ablation device 
with 3.6 V DC rechargeable batteries, Epiture Easytouch™, to create laser light for 
transdermal drug delivery as shown in Figure 2.13. The laser for this device is Er:YAG 
(2940 nm) and performs with single laser pulse, which transfers 1 J ±20% of energy to 
skin within 600 µs ±20%. Norwood Abbey is currently performing clinical studies with 





Figure 2.13 (a) Epiture Easytouch™, laser assisted drug delivery (LAD) system 
developed by Norwood Abbey and (b) the demonstration of LAD on hands (Revised 





Similar to this approach using laser energy, TransPharma Medical designed the 
portable skin ablation device, ViaDerm patch system (Figure 2.14), operated by radio-
frequency (100-500 kHz), which generates electrical energy that passes through cells in 
the upper skin layers via an array of electrodes, which then induces ionic vibrations in the 
skin cells resulting in local heating, liquid evaporation, and the creation of microchannels 
21, 92, 93 to the inner skin within around 100 ms of the total operation time. TransPharma 
Medical is studying transdermal delivery of various molecules such as Granisetron HCl, 





Figure 2.14 Radio-frequency assisted transdermal drug delivery system. (a) 






As another approach based on electrical energy, Altea Therapeutics developed the 
PassPort® patch system, in which an electric device (Figure 2.15 (b)) supplies electrical 
energy to a micron size heating element (Figure 2.15 (a)). The heating element then 
generates thermal ablation energy to make micro size pores 91 in the skin on the basis of 
ohmic heating of electrically conductive material. The skin ablation depth by PassPort® 
will be determined by the duration of current flow through the heating elements and the 
electrical properties of material used for heating elements. Altea Therapeutics began 
Phase I clinical study of insulin and hydromorphone patch in 2003 and completed Phase 





Figure 2.15 Passport® patch designed by Altea Theapeutics. (a) Ohmic heating 






2.5 Summary of transdermal delivery technologies 
The transdermal administration of small size drugs has been used in conjunction 
with the diffusion mechanism of skin for many years and stratum corneum has been 
known as the main barrier of skin for the delivery of the large molecules, including 
biopharmaceuticals. These barrier properties have been of interest in developing 
technologies for the enhanced transdermal drug delivery using mechanisms such as 
disruption of stratum corneum integrity, breakage of stratum corneum, and removal of 
stratum corneum. 
Methods that disrupt stratum corneum integrity like chemical enhancers, 
sonophoresis, and iontophoresis, make a pathway for drug diffusion through stratum 
corneum after its barrier properties are changed. However, stratum corneum is still 
present in these methods, so delivery of large molecules remains a challenge even though 
they are successful for fast delivery of small molecules and local treatments. Methods 
that break or remove stratum corneum, such as microneedles, jet injection, mechanical 
microenhancer, and laser/RF/heat ablation, overcome the skin barrier simply by the 
physical breakage of stratum corneum, allowing delivery of large molecules with these 
techniques. Therefore, various biopharmaceuticals are in the clinical trials currently using 
these types of methods for enhanced transdermal delivery.  
However, these methods for the breakage or removal of stratum corneum have 
focused mainly on the stratum corneum alterations, thus the efficient delivery of 
biopharmaceuticals is still in the development stage. Since most biopharmaceuticals are 
sensitive molecules, they can lose integrity during the process of combining them with 
these delivery technologies. For example, microneedles have successfully shown the 
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controlled breakage of stratum corneum, but the amount of dose available, due to the 
small size of the system and the stability of biomolecules may create problems in the 
future. In the case of ablation of the skin with external energy to remove stratum corneum, 
the highly controlled removal of the skin barrier would be necessary to prevent deeper 




3.1 Dissolving microneedles 
3.1.1 Fabrication of microneedles 
3.1.1.1 Molding 
Micromolds were fabricated using photolithography and molding processes 
described in the previous study 94. A female microneedle master-mold was structured in 
SU-8 photoresist (SU-8 2025, Microchem, Newton, MA) by UV exposure to create 
conical (circular cross section) or pyramidal (square cross section) microneedles tapering 
from a base measuring 300 µm in width to a tip measuring 25 µm in diameter over a 
microneedle length of 600-800 µm. A male microneedle master-structure made of 
polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, Midland, MI) was created 
using this mold. The male PDMS master-structure was sputter-coated (601 Sputtering 
System, CVC Products, Rochester, NY) with 100 nm of gold to prevent adhesion with a 
second PDMS layer cured onto the male master-structure to create a female PDMS 
replicate-mold. To modify the master-structure, a replicate of master-structure was made 
out of PLA polymer with the melting technique 28, and then the PLA replicate was 
electroplated with nickel after coating with gold. This thickened structure was replicated 
with PLA again after PDMS molding and the tip of PLA replicates of thickened 
microneedle structure was sharpened with reactive ion etching techniques 28.  
With the male master-structure made of PDMS or PLA, a female PDMS mold was 
fabricated. Excess PDMS on the female replicate-mold was trimmed so that the mold fit 
within the 27-mm inner diameter of a 50 ml conical tube (Corning Inc., Corning, NY) or 
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the bottom area of the rectangular swing bucket (FL400, Eppendorf, Westbury, NY). The 
metal-coated male master-structure was repeatedly used to make replicate-molds that 
were repeatedly used to make microneedle devices.  
 
3.1.1.2 Preparation of microneedle matrix 
To serve as microneedle matrix materials, ultra-low viscosity 
carboxymethylcellulose (CMC, Cat No. 360384, Aldrich, Milwaukee, WI), amylopectin 
(Cat No. 10120, Fluka, Steinheim, Germany) and bovine serum albumin (BSA, Sigma, St. 
Louis, MO) were dissolved in deionized water. For the mixture matrix of microneedles, 
trehalose (Cat No. T9531, Sigma, St. Louis, MO) was dissolved with CMC together in 
deionized water.  
Water was then evaporated off until the concentration of solute (e.g., CMC) was 
approximately 27 wt%, which resulted in a viscous hydrogel. CMC was concentrated by 
heating at 60-70oC at ambient pressure or vacuuming at -50 kPa at room temperature. 
Amylopectin and BSA were concentrated only by the heating method at 60-70oC or 37oC, 
respectively. Solute concentration was determined by measuring solution mass before 
and after evaporation. Viscosity of concentrated hydrogels was measured using a Couette 
viscometer (Physica MCR300, Anton Paar Physica, Ostfildem, Germany).  
In some cases, a model drug was added by hand mixing to solubilize or suspend the 
compound in the concentrated hydrogel. Three model drugs were added at final 
concentrations of 0.15-30 wt% sulforhodamine B (Molecular Probes, Eugene, OR), 20 
wt% BSA (Sigma), or 5 wt% lysozyme (Sigma). The term “model drug” is used to 
indicate that these compounds have physicochemical and transport properties 
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representative of certain classes of drugs, but not to suggest that these compounds have 
pharmacological activity representative of drugs. For human growth hormone delivery, 
recombinant human growth hormone, hGH (Genotropin®, Pfizer, Groton, CT) was 
provided from Division of Pediatric Endocrinology in Emory University School of 
Medicine. Human growth hormone was added to the concentrated hydrogel of CMC or 
mixture of CMC and trehalose (50:50) at final concentrations of 2-10 wt%. 
 
3.1.1.3 Casting 
To mold microneedles from concentrated hydrogels, 100-300 mg of hydrogel was 
placed on a female PDMS mold in a conical centrifuge tube (Corning) and centrifuged in 
a 45o angled rotor (GS-15R, Beckman, Fullerton, CA) or on the bottom of swing bucket 
(Eppendorf) and centrifuged in a swing-bucket rotor (A-4-38, Eppendorf, Westbury, NY) 
at 3000×g and 25-37oC for up to 2 h to fill the microneedle mold cavities and dry the 
hydrogel. 
To prepare microneedles with model drug encapsulated only within the 
microneedles and not in the backing layer, 8-10 mg of hydrogel mixed with model drug 
was filled just into the microneedle cavities in the mold and then dried under 
centrifugation for up to 30 min. Residual hydrogel on the surface of the mold was 
removed with dry tissue paper (Kimwipes, Kimberly-Clark, Roswell, GA) and 100-200 
mg pure hydrogel without drug was then applied and dried onto the mold to form the 
backing layer. To prepare microneedles with model drug encapsulated only in the 
backing layer and not within the microneedles, the same two-step process was followed, 
except pure hydrogel was filled into the microneedle mold cavities and a hydrogel mixed 
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with model drug was used to form the backing layer. The fabrication process from the 






Figure 3.1 The fabrication processes of dissolving microneedles (I: Preparation of 





3.1.2 Microneedle mechanics 
3.1.2.1 Microneedle failure 
Mechanical failure tests were performed with a displacement-force test station 
(Model 921A, Tricor Systems Inc., Elgin, IL, USA), as described in previous study 95. A 
3×3 array containing 9 microneedles was attached to the mount of a moving sensor and 
an axial force was applied to move the mount at a speed of 1.1 mm/s. The mount pressed 
the microneedles against a flat, rigid surface of stainless steel oriented perpendicularly to 
the axis of mount movement. The test station recorded the force required to move the 










3.1.2.2 Microneedle skin insertion  
To determine if microneedles insert into skin, CMC pyramidal microneedles (600 
µm height, 300 µm base width, and 600 µm center-to-center spacing) in a 10×10 array 
were inserted with IACUC approval into full-thickness cadaver pig skin without 
subcutaneous fat that was shaved (series 8900, WHAL, Sterling, IL) and affixed under 
mild tension to a wooden plate using 1 cm long screws. Microneedles were inserted by 
pressing against the microneedle backing layer with a thumb using a force of 
approximately 1.5 N and then removed immediately after the insertion. The site of 
microneedle insertion on the skin surface was exposed for 10 min to a red tissue-marking 
dye (Shandon, Pittsburgh, PA, USA) that selectively stains sites of stratum corneum 
perforation. After wiping residual dye from the skin surface with dry tissue paper, skin 
was viewed by brightfield microscopy (SZX12, Olympus). 
Skin samples were prepared for histology by freezing in histology mounting 
compound (Tissue-Tek, Sakura Finetek, Torrance, CA) and slicing into 20-µm thick 
sections (Cryo-star HM 560MV, Microm, Waldorf, Germany) and then viewed by 
brightfield microscopy (E600, Nikon, Tokyo, Japan). 
 
3.1.2.3 Simulation of microneedle critical buckling load 
Critical buckling load, Pcr, of microneedles was simulated during axial loading 
using analytical methods of Smith (ref). For the fixed-free case, where the microneedle 
base was fixed in position and the microneedle tip could move freely, the square-based 
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pyramidal and circle-based conical geometries were modeled using the equations for Pcr5 
of case 3 and Pcr7 of case 5 in Appendix A of Smith 96, respectively:  
 
Pcr5 = E (120(H2(H22(H2-2H1)+2H13)-H14) + π2(20(H2(H22(-H2+H1)-H13)+H14) + 
π2(H2(H2(H2(H2+H1)+H12)+H13)+H14)))/(240π2L2)   (pyramidal geometry) (1) 
 
Pcr7 = E (120(R2(R22(R2-2R1)+2R13)-R14) + π2(20(R2(R22(-R2+R1)-R13)+R14) + 
π2(R2(R2(R2(R2+R1)+R12)+R13)+R14)))/(80πL2)          (conical geometry)  (2) 
 
Here, E is Young’s modulus; L is microneedle length; H1and H2 are microneedle 
widths at the base and tip of pyramidal microneedles, respectively; and R1 and R2 are 
radii at the base and tip of conical microneedles, respectively. Young’s modulus of CMC 
microneedles was determined to be 1 GPa by direct measurement (MicroTester, Instron 
5548, Norwood, MA) using bulk CMC prepared using the same casting process used to 
make microneedles. Young’s modulus of PLA microneedles was previously determined 
to be 5 GPa 28. Tip width and diameter of pyramidal and conical microneedles, 
respectively, were estimated both to be 25 µm based on microscopic examination.  
 
3.1.3 Drug release from microneedles 
3.1.3.1 Imaging bolus release from dissolving microneedles 
CMC pyramidal microneedles (600 µm height, 300 µm base width, and 600 µm 
center-to-center spacing) in a 6×6 array were inserted by hand into pig cadaver skin. Just 
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the microneedles, and not the backing layer, contained sulforhodamine B at 0.15 wt% on 
a dry basis, such that each microneedle contained 0.04 µg of sulforhodamine and the 36-
needle array contained 1.44 µg of sulforhodamine. After 5 min, the microneedles were 
removed from skin and the skin sample was examined histologically. In a separate set of 
experiments, the shape of microneedles was also observed after 10 s, 1 min, 15 min, and 
60 min insertion into the skin by light microscopy (SZX12, Olympus). 
 
3.1.3.2 Imaging and quantification of sustained release from microneedle patches 
To image long-term release from dissolving microneedles into skin, 
sulforhodamine B was encapsulated within the needles and the backing layer at 0.15 wt% 
in a 6×6 array of CMC pyramidal microneedles (600 µm height, 300 µm base width, and 
600 µm center-to-center spacing). The microneedle device contained 15 µg of 
sulforhodamine. The microneedles were inserted into pig cadaver skin by hand, covered 
with dermal tape (Blenderm, 3M Health Care, St. Paul, MN), and kept at room 
temperature for up to 12 h. Next, the microneedle device was removed and skin was 
examined histologically.  
To quantify sulforhodamine release, a 7×7 array of CMC or amylopectin pyramidal 
microneedles (600 µm height, 300 µm base width, and 600 µm center-to-center spacing) 
was prepared with a backing layer of approximately 300 µm thickness. Sulforhodamine B 
was encapsulated within the needles and the backing layer at 10 wt%, which 
corresponded to 1 mg of sulforhodamine in the microneedle device weighing 10 mg. 
Alternatively, sulforhodamine was encapsulated only within the backing layer at 10 wt% 
and 30 wt%, which corresponded to almost 1 mg and 3 mg of model drug per device, 
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respectively. Microneedles were inserted by hand into heat-stripped human cadaver 
epidermis 97 (Emory University Body Donor Program, Atlanta, GA) with IRB approval. 
Microneedles were secured to skin with dermal tape and the microneedle-skin assembly 
was placed in a Franz diffusion chamber (Permegear, Hellertown, PA) at 32oC. 
Phosphate-buffered saline (PBS) in the receptor compartment of the Franz chamber 
contained 0.01 M sodium azide as an anti-bacterial agent and was sampled periodically 
for up to 7 days to determine sulforhodamine flux by spectrofluorimetry (QM-1, Photon 
Technology International, South Brunswick, NJ). 
 
3.1.4 Protein stability and activity  
3.1.4.1 Circular dichroism  
The secondary structure of lysozyme was examined by spectropolarimetry (JASCO, 
J-810, Tokyo, Japan) after encapsulation and release from dissolving microneedles. CMC 
pyramidal microneedle devices weighing 5 mg that encapsulated lysozyme at a mass 
fraction of 5 wt% were completely dissolved in 50 ml PBS at room temperature for 10 
min and filtered by centrifugal filtration (Centricon YM-50, Millipore, Bedford, MA, 
USA) at 1000×g and room temperature for 10 min to isolate lysozyme (14.3 kDa) from 
the dissolved CMC matrix material (90 kDa average molecular mass). After determining 
lysozyme concentration by Lowry protein assay 98, PBS was added to dilute to lysozyme 
to 20 µg/ml. CD spectra were taken for (1) untreated lysozyme, (2) lysozyme 
encapsulated in microneedles that were dissolved 1 h after fabrication, (3) lysozyme 
encapsulated in microneedles that were dissolved after 60 days of storage at ambient 
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conditions (23±2oC and 38±5% relative humidity), and (4) lysozyme thermally treated at 
80oC for 30 min to cause irreversible denaturation 99.  
 
3.1.4.2 Lysozyme activity  
Enzymatic activity of lysozyme encapsulated within CMC microneedle devices was 
tested with EnzCheck lysozyme assay kit (Molecular Probes). Microneedle devices 
weighing 5 mg that contained lysozyme encapsulated at a concentration of 5 wt% were 
completely dissolved in PBS at room temperature for 10 min. PBS was added to dilute 
each sample to 0.05 µg/ml lysozyme and 0.95 µg/ml CMC. Lysozyme activity was 
assayed using 1 ml solution samples for: (1) untreated lysozyme, (2) untreated lysozyme 
(0.05 µg) and CMC hydrogel (0.95 µg) mixed, and dissolved together, (3) lysozyme 
encapsulated in microneedles that were dissolved 1 h after fabrication, and (4) lysozyme 
encapsulated in microneedles that were dissolved after 60 days of storage at ambient 
conditions.  
 
3.2 Human growth hormone delivery  
3.2.1 Animal model 
For in vivo delivery of human growth hormone, wild-type male hairless rat (CD® 
Hairless Rat, Charles River) was selected as an animal model and this study was 
approved by the Institutional Animal Care and Use Committee of Georgia Tech. All rats 
at 10-11 weeks after the birth were purchased from Charles River and weighed at 280-
340 g and they were kept freely with water and food for at least 48 hours after they were 
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transferred from Charles River to Georgia Tech facility. They were anesthetized with 
isoflurane, ISOTHESIA™ (Butler Animal Health Supply, Dublin, OH) for the insertion 
of microneedles or the skin bandaging and anesthesia was maintained during the 
measurement of skin impedance for the skin resealing study and the blood draw for the 
pharmacokinetics study. After the measurement of skin impedance and the blood draw, 
they were euthanized with carbon dioxide gas. For the study of skin reaction after the 
insertion of microneedles, the skin inserted with microneedles was cut off, fixed by using 
formalin, embedded with paraffin, and sectioned for histology to investigate the skin 
reaction. See the section 3.2.5 for the detail.  
 
3.2.2 Skin Resealing 
3.2.2.1 Skin Bandaging 
The animal skin was covered with the bandaging, which is necessary to secure the 
microneedles system on the animal skin to maintain the occlusion state as well as to 
prevent the reach of animal’s limbs and any artifact. In some cases, a rodent e-collar (404 
¼VS, Webster Veterinary, Sterling, MA) was placed around the animal neck for 
maximally 24 hours. Microneedles were inserted into the skin on the torso of the animal 
with the same method used in described in the section 3.1.2.2 and they were covered with 
a dressing, Tegaderm™ (3M Health Care, St. Paul, MN), and then the torso of the animal 
was bandaged with self-adherent wrap, Coban™ (3M Health Care, St. Paul, MN) and 
fixed with porous adhesive tape, Zonas (Johnson and Johnson, Skillman, NJ) as shown 
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Figure 3.3. This was performed with the training from Prof. Ajay K. Banga at Mercer 





Figure 3.3 Hairless rat bandaging processes (1: Determination of site, 2: Application 
of dressing, 3: Wrapping, and 4: Fixing with tape). 
 
3.2.2.2 Measurement of skin impedance 
The skin resealing after the insertion of CMC microneedles was estimated with the 
skin impedance measurement by using an electrode impedance meter, Prep-Check (EIM-
105, General Devices, Ridgefield, NJ) applying 30 Hz AC current modified with a 200 
kΩ resistor (Ack Electronics, Atlanta, GA) in parallel to enable the measurement of skin 
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impedance greater than 200 kΩ. The reference electrode coated with highly conductive 
gel, Superior Silver® Electrode with PermaGel™, (Uni-Patch, Wabasha, MN) was 
attached to the rat skin and a disposable Ag/AgCl dry electrode (T3404, Thought 
Technology, Montreal, Quebec, Canada) for each category was covered on the site of the 
microneedles insertion with the same distance from the reference electrode. The 
measurement of skin impedance was performed by connecting the reference electrode 
and a dry electrode for each category to the impedance meter, Prep-Check. 
The skin impedance was measured for 4 categories; (A) CMC microneedles were 
inserted for 24 hours without the measurement. (B) CMC microneedles were inserted and 
immediately removed at 0 h. Then the skin impedance was measured for 24 h. (C) The 
impedance of intact skin with no treatment was measured for 24 h. (D) CMC 
microneedles were inserted, immediately removed, and covered with the CMC backing 
for 24 h without the measurement. The skin was occluded for the first 24 h and 
unoccluded for the second 24 h. In category (A) and (D), the skin impedance was 
measured only for the second 24 h after the system was removed at 24 h. In category (B) 
and (C), it was measured for the first 24 h with the occlusion and for the second 24 h 
without the occlusion.  
 
3.2.3 Human growth hormone activity 
3.2.3.1 SDS-PAGE 
To check the change of the primary structure of hGH encapsulated in CMC 
microneedles, the electrophoresis with unprocessed and processed hGH was performed 
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by using a SDS-PAGE device, Owl mini-vertical Electrophoresis (P8DS, Thermo 
Scientific, Waltham, MA). The unprocessed hGH is hGH before the fabrication of 
dissolving microneedles and the processed hGH is hGH encapsulated in CMC 
microneedles. The hGH solution at the concentration of 1 mg/ml was made with 
unprocessed and processed hGH by using sample loading buffer (Tris-Glycine SDS, 
Pierce, Rockford, IL). Then 20 µg hGH of each solution (20 µl) and the unstained 
standard solution (20 µl), Mark 12™ (Invitrogen, San Diego, CA) were pipetted into each 
well of a pre-cast gel with a cassette, Precise™ Protein Gel (25204, Pierce, Rockford, IL), 
which was inserted into the SDA-PAGE device running with running buffer, BupH™ 
(Tris-HEPES-SDA, Pierce, Rockford, IL) and 120 V of the power supply (FB300, 
Fischer Scientific, Dubuque, IA) for approximately 40 min . After running, the gel was 
washed three times for 5 min each in 200 ml of deionized water and stained with 
commassie blue, SimplyBlue™ (Invitrogen, San Diego, CA). 
 
3.2.3.2 Nb2 Cell growth 
The functional activity of hGH was estimated with the hGH-stimulated growth of 
Nb2 rat lymphoma cells 100, 101, purchased from Sigma-Aldrich (Cat. No. 97041101, 
Sigma-Aldrich). The basic steps of this study are composed of three phases; (I) the cell 
growth with bovine serum based culture medium for verifying the normal growth rate of 
Nb2 cell (3 days), (II) the transfer of Nb2 cell to horse serum based culture medium to 
ensure stationary cell growth (1 day), and (III) the addition of hGH solution to Nb2 cell 
culture based on solely horse serum and no bovine serum for checking the growth-
promoting activity of hGH inducing to resume the cell growth (3 days). The number of 
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viable Nb2 cell at each phase was measured using a cell viability analyzer, Vi-CELL™ 
(Beckman coulter, Miami, FL). 
The culture medium for phase I was prepared with Fischer’s medium (Quality 
Biological Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS, 
Atlanta Biologicals, Atlanta, GA) and 10-4 M 2-mercaptoethanol (Sigma-Aldrich, 
Milwaukee, WI). The culture medium for phase II was prepared with Fischer’s medium 
supplemented with 1 % FBS, 10% horse serum (HS, Mediatech Inc., Herndon, VA), and 
10-4 M 2-mercaptoethanol. For phase III, the culture medium was prepared without FBS; 
Fischer’s medium, 10% HS, and 10-4 M 2-mercaptoethanol only. Nb2 cells were cultured 
as suspension in a humidified atmosphere of 95% air and 5% CO2 at 37oC. The hGH 
solution was prepared with the culture medium used for phase III and added to Nb2 cell 
culture with the designated concentration ranging from 1 pg/ml to 3000 pg/ml of hGH 
after Nb2 cell in phase II was transferred to the culture medium of phase III.  
When Nb2 cells were transferred to the next phase medium, they were centrifuged 
for 3 min at 300×g with a centrifuge (GS-15R, Beckman, Fullerton, CA) and 
supernatants were aspirated using a vacuuming flask. Then, Nb2 cells were rinsed with 
deionized water twice to prevent the previous medium from mixing with the next phase 
medium when they were transferred to the next phase medium. The increased population 
of Nb2 cell due to the addition of hGH solution was calculated with the comparison of 
two populations of Nb2 cell at the beginning of phase III before the addition of hGH 
solution and at the third day of phase III. The processes are summarized in Figure 3.4. 
The five different groups of hGH solutions were added to Nb2 cell culture in phase 
III; (1) Placebo solution having only processed CMC, (2) unprocessed hGH solution 
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(negative control), (3) unprocessed hGH solution mixed with processed CMC, (4) 
processed hGH and CMC solution (reconstitution of hGH encapsulating CMC 
microneedles), and (5) processed hGH and CMC solution (reconstitution of hGH 
encapsulating CMC microneedles after 3 months storage at ambient conditions (23±2oC 
and 38±5% relative humidity)). For all groups, the mass ratio of hGH to CMC is 5 to 95, 
which means that 5 wt% hGH was loaded in CMC microneedles. The processed CMC is 
the solidified CMC hydrogel cast by using the same method used to fabricate CMC 










3.2.4.1 Administration of hGH  
hGH encapsulating microneedles were fabricated with the method described in the 
section 3.1.1.2 and 3.1.1.3. For the matrix material of microneedles, CMC only or 
CMC/trehalose mixture hydrogels were prepared. To administer hGH to hairless rats, 5 
groups were designed; (Group 0) – the subcutaneous injection of the reconstitution of 
unprocessed hGH (negative control group), (Group 1) – the insertion of hGH 
encapsulating CMC microneedles, (Group 2) – the subcutaneous injection of the 
reconstitution of hGH encapsulating CMC microneedles after 15 months storage at 
ambient conditions (23±2oC and 38±5% relative humidity), (Group 3) –  the insertion of 
hGH encapsulating CMC/trehalose microneedles, and (Group 4) – the subcutaneous 
injection of the reconstitution of hGH encapsulating CMC/trehalose microneedles. The 
subcutaneous injection for group 0, 2, and 4 was performed by using a 27G hypodermic 
needle (Becton Dickinson, Franklin Lakes, NJ) and dissolving microneedles 
encapsulating hGH for group 1 and 3 were inserted with  a thumb push method describe 
in the section 3.1.2.2. 
 
3.2.4.1 Analysis of plasma concentration hGH (ELISA) 
Blood of hairless rat was drawn at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 h after hGH of 
each group was administered by hypodermic needle injection or microneedles insertion 
and the volume of each blood collection was determined as 120 µl in order to obtain the 
minimum volume (60 µl) of serum for ELISA and not to exceed the maximum volume of 
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1.2 ml blood over 24 h. Blood was drawn from the saphenous vein in the tail by cutting it 
slightly with a surgical blade (Butler Animal Health Supply, Dublin, OH) and collected 
with a small tube, CAPIJECT® (T-MG, Trumo Medical Corp., Elkton, MD) with gel 
barrier inside it used for the separation of serum and blood cells. The blood collected with 
a CAPIJECT® tube was left at the room temperature for 2 h, the necessary time for blood 
to clot, and then it was spun at 1200×g for 10 min with a centrifuge (5415 R, Eppendorf, 
Westbury, NY) to obtain the rat serum. The rat serum was transferred into a safe-lock 0.5 
ml conical tube (Eppendorf) and stored at -70oC until ELISA analysis. 
The concentration of hGH in rat serum was measured with an enzyme-linked 
immunosorbent assay kit, ACTIVE® human growth hormone ELISA (DSL-10-1900, 
Diagnostic Systems Laboratories Inc., Webster, TX). This kit is specific for human 
growth hormone without detecting endogenous rat growth hormone. Areas under the 
concentration curves (AUCs) were computed with the area of trapezoid formed between 
data points. The color intensity of samples at the final step of ELISA was measured with 
a microplate reader, iMark™ (Bio-Rad, Hercules, CA).  
 
3.2.5 Skin reaction 
To study skin reactions that may occur after the insertion of hGH dissolving 
microneedles, the insertion site was imaged by a digital camera (FZ50, Panasonic, Tokyo, 
Japan) at 24, 27, 30, 36, and 48 h for the first 24 hours and every day for the week. After 
euthanasia, the treated skin samples were prepared for histology by tissue fixing with 
10% neutral buffered formalin, PROTOCOL™ (Fisher Healthcare, Swedesboro, NJ), 
paraffin embedding with tissue embedding system (Histocentre 2, Shandon), slicing into 
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1 µm thick sections with rotary microtome (HM355S, Microm, Waldorf, Germany), and 
staining with hematoxylin and eosin (H&E). Then, they were viewed by brightfield 
microscopy (E600, Nikon, Tokyo, Japan) to check visually the skin reaction such as 
erythema and edema with focusing on the area near the insertion site by using the 
subjective rating method 102. 
 
3.3 Micro skin ablation 
3.3.1 Micro skin ablation (MSA) device 
3.3.1.1 Design and fabrication of MSA 
To create the energy impact required for selective ablation of skin, an arc discharge 
phenomenon was believed to be a good model for the energy source. The key points of 
the design of MSA device were: (1) the rapid generation and extinction of arc discharge 
in the minimized scale and (2) the controlled utilization of arc energy. This design was 
enabled by the modification of the laminated gas generator actuators system 103 
developed by the MicroSensors and MicroActuators (MSMA) research group in the 
School of Electrical and Computer Engineering of Georgia Tech. All fabrication and 
device characterization for the MSA system were performed in collaboration with the 
MSMA group. 
The MSA system has two major parts: the MSA device and a power supplying 
system. The MSA device was designed to have two basic elements; a microchamber 
where arc discharge occurs and a nozzle by which the energy medium ejected from 
microchamber is guided to drive the energy impact to the skin surface. Two methods 
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were employed to fabricate the MSA device: laser micromachining to pattern layers and 
lamination technologies to integrate the layers. For the laser micromachining, two kinds 
of lasers were used to pattern all the layers of the micro skin ablation device: A CO2 gas 
laser (LS500 Laser Engraving System, New Hermes-Gravograph, Duluth, GA), which 
was used to cut polymer-based material and a solid state infrared laser (Nd:YLF, 
Resonetics Maestro, Nashua, NH) which was used to process metals. The microchamber 
was made by patterning and integrating 5 layers; a chamber layer (Biaxially-oriented 
polyethylene terephthalate, BoPET), two electrode layers (Metal), and two backing layers 
(Polymethylmethacrylate, PMMA). The geometry for the microchamber and the nozzle 
was patterned on 250 µm thick BoPET film, Mylar sheet (Goodfellow, Oakdale, PA). 
The electrode layers to supply the energy for creating arc discharge were made using a 
25-50 µm thick metal sheet (McMaster-Carr, Elmhurst, IL) such as brass, nickel and 
titanium. For backing layers to maintain structural integrity of the device during arc 
discharge phenomenon, a 1.5 mm thick PMMA sheet (Goodfellow, Oakdale, PA) was 
used. 
To provide electrical energy to the MSA device for skin ablation energy, a circuit 
(Figure 3.5) was designed with three main components; a high voltage DC power supply 
(Kiethley Instruments, Cleveland, OH) to provide the electrical energy, a capacitor (Digi-
key, Thief River Falls, MN) to store the electrical energy with the maximum of 250 V 
and provide it to the MSA microchamber, and a MOSFET (IRG4P254, International 




All details of the fabrication work and the optimization of parameters in MSA 
function are described in Chapters 3 and 4 of the dissertation “Laminated chemical and 
physical micro-jet actuators based on conductive media” 104 (Gadiraju, Priya, School of 
Chemical and Biomolecular Engineering, Georgia Institute of Technology).  
 
3.3.1.2 Design of MSA function 
The MSA system is based on the rapid generation and extinction of energy caused 
by the arc discharge phenomenon. The energy medium is ejected from the microchamber 
in the form of thermal and mechanical energy 104 so that the MSA function is based on 
thermal or mechanical effects. To utilize this energy impact for controlled skin ablation, 
four different MSA scenarios were designed in combination with the masking system, as 
shown in Table 3.1. Three different types of metal sheets (25 µm thickness); tungsten 
(3N8), titanium (3N7), and nickel (3N, ESPI metals, Ashland, OR) were tested as 
materials for the masking system to obtain the localized and selective removal of stratum 
corneum. The fabrication of the masking system was performed by using the same 









Figure 3.5 (a) Power supply for controlling the electrical energy and (b) schematic of 




Table 3.1 Micro skin ablation using the energy impact from arc discharge 
 
Group 1 2 3 4 
Schematic 
Description 
    
Localization Non-localized localized Non-localized localized 
Mask No mask Windows Solid Solid and Windows 
Ablation 
Effect 
Thermal + Mechanical  Thermal  
 
 
3.3.2 Characterization of thermal ablation function 
3.3.2.1 Measurement of thermal energy temperature 
The temperature of the energy impact triggered by arc discharge occurring in the 
MSA device was measured using irreversible temperature indicating paper, THERMAX® 
(Thermographic Measurements Ltd., Glenview, IL). This paper is coated with a heat 
sensitive white polymer, that melts at specific temperature when in contact with a hot 
medium, allowing the black background to appear. For the thermal and mechanical 
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ablation scenario, temperature indicating papers were exposed to the medium as it 
escapted from the microchamber so that the temperature of the ejected medium was 
measured. In the thermal ablation scenario, the papers were placed under a solid mask 
and the temperature of the thermal energy transferred through the solid mask was 
measured. The detectable range of temperature by THERMAX® was from 30oC up to 
290oC, which is the available maximum value. 
 
3.3.2.2 Simulation of thermal energy temperature 
The temperature of the energy released from the MSA microchamber and the 
temperature profile in the skin layer were simulated by conversion of the electrical 
energy to the thermal energy using a semi-infinite model of heat transfer in the skin.  
The consumed energy of the MSA device was estimated with Joule’s law (P = V·I) 
by the change of voltage and current in the device during operation. The operating 
voltage in the power supply circuit was adjusted, at a range from 100 V to 200 V, and the 
length of the 5 V pulse applied to MOSFET was 1.5 ms. The voltage change across the 
microchamber was measured by two voltage divider circuits placed on either side of the 
microchamber (Figure 3.5 (b)). The current was estimated by the measured voltage drop 
across MOSFET and the technical data sheet of MOSFET supplied from the 
manufacturer (International Rectifier, El Segundo, CA). The voltage drop across the 
microchamber and MOSFET was measured by using a 12-bit data acquisition board 
(DAQ MIO-16E, National Instruments, Austin, TX) and a junction box (BNC-2090, 
National Instruments, Austin, TX) and recorded with LabVIEW software (National 
Instruments, Austin, TX).  
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The heat transfer from the ejected medium to the skin layers was computed with 
simulation software, ANSYS® (ANSYS Inc., Canonsburg, PA), by using a transient 
semi-infinite model with the boundary condition that the temperature at the outer surface 
of the solid mask is constant and the same as the temperature of the ejected medium 
during MSA operation. The heat conductivity, heat capacity, and density of the solid 
mask, the windows mask, stratum corneum, and epidermis were assumed to be constant 
over the entire temperature range. All thermal properties of each layer are in Table 3.2. 
 
Table 3.2 Thermal conductivity, heat capacity, density, and thickness of tungsten, 
titanium, stratum corneum, and viable epidermis 105, 106 used for the simulation of 
the temperature profile during the operation. 
 






174 21.9 0.123 0.42 
Density (kg/m3) 19300 4500 1280 1090 
Heat Capacity (J/kg·K) 132 522 1880 3350 




3.3.3. Skin ablation 
3.3.3.1 Thermo mechanical or thermal ablation 
The skin ablation system was operated in the following order. First, the 
microchambers were filled with an electrically conductive medium, PBS. Then, the 
assembled circular disk unit with multiple microchambers was combined with the 
piezoelectric force sensor (9144A21, Kistler Instruments, Amherst, NY) to measure the 
mechanical energy exerted by the arc discharge phenomenon. Finally, two electrodes in 
the microchamber were connected to the power supplying circuit as shown in Figure 3.6. 
The full-thickness cadaver pig skin without subcutaneous fat was shaved (series 
8900, WHAL, Sterling, IL) with IACUC approval and trimmed to fit the size of the 
nozzle exit hole. The pig skin sample was placed on the nozzle of the microchamber and 
pushed slightly by using a cotton swab, Critical Swab® (VWR, West Chester, PA) to 
prevent the skin sample from moving out of place. Then the pig skin was treated with the 
arc discharge ablation system.  
As described in Table 3.1, the pig skin samples were exposed to the medium 
ejected from the microchamber without (Group 1) or with the window mask (Group 2) to 
study the thermal and mechanical skin ablation effect. For the thermal ablation effect, the 
solid mask was placed on the surface of the pig skin (Group 3) and the combined 
masking system of solid and window masks (Group 4) were tested to investigate both 







Figure 3.6 Micro skin ablation device combined with a power supply circuit and a 
force sensor 104. 
 
 
3.3.3.2 Imaging micro skin ablation  
To visualize the ablation effect of the energy impact on stratum corneum, the 
surface of the pig skin samples were viewed by brightfield microcopy (SZX12, Olympus). 
To verify the removal of stratum corneum, the delivery of a hydrophilic model drug, 
sulforhodamine was performed. The drug formulation of transdermal delivery consisted 
of 30 mg of sulforhodamine and 970 µl of viscous solution made with 10% CMC and 
deionized water, which was applied to the ablated pig skin samples for 12 hours. For 
visualization of the localized removal of stratum corneum, the delivery time was reduced 
to 30 min to image the skin surface with the distinct ablation sites. After the brightfield 
observation of the pig skin surface, each pig skin sample was prepared for histology and 
sectioned to determine the selective removal of stratum corneum by histological methods. 
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Skin samples were prepared by freezing in histology mounting compound (Tissue-Tek, 
Sakura Finetek, Torrance, CA) and slicing into 20-µm thick sections (Cryo-star HM 
560MV, Microm, Waldorf, Germany) which were mounted and viewed by brightfield 
and fluorescent microscopy (E600, Nikon, Tokyo, Japan). 
 
3.3.4 Skin permeability and transdermal flux 
This experiment was designed to study how efficiently the MSA device can deliver 
hydrophilic or large size drug through the skin. The skin permeability of two different 
molecular weight compounds, sulforhodamine (Molecular Probes, Eugene, OR) and 
Texas Red BSA (Molecular Probes, Eugene, OR) was measured using a Franz diffusion 
chamber (Permegear, Hellertown, PA) and human skin with IRB approval.  
First, heat-stripped human cadaver epidermis 97 was used as the skin membrane. 
The untreated epidermis and epidermis treated with the MSA system were prepared and 
placed between the donor and the receptor compartment of Franz diffusion cell. The 
donor compartment was filled with the solution of sulforhodamine (10-3 M) or Texas Red 
BSA (10-4 M) with PBS as models of low and high molecular weight model drugs, 
respectively, and the receptor compartment was filled with PBS. Assuming that the 
steady state of flux from the donor compartment to the receptor compartment is within 
three hours, the content in the receptor compartment was sampled after 1 hour and the 
concentration of model drug was analyzed by using a spectrofluorimetry (QM-1, Photon 
Technology International, South Brunswick, NJ). The skin permeability experiment was 
performed with human full thickness skin to have better approximation to the in-vivo 
situation. With the exception of the type of skin membrane, all protocols were the same 
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as those performed with epidermis layer alone. The diffusion process of each model drug 
through human full thickness skin, ablated full thickness skin, and epidermis-striped skin 
(dermis only) was visualized using histological skin images, which were prepared by the 




4.1 Dissolving microneedles results 
Four materials-related criteria were determined for the design of microneedles 
suitable for self-administration of biotherapeutics from a minimally invasive patch: (1) 
gentle fabrication to avoid damaging sensitive biomolecules, (2) sufficient mechanical 
strength for insertion into the skin, (3) controlled release for bolus and sustained drug 
delivery, and (4) rapid dissolution of microneedles made of safe materials. Guided by 
these criteria, two polysaccharides, carboxymethylcellulose and amylopectin were 
selected because they are biocompatible materials with a history of use in FDA-approval 
parenteral formulations 107, 108, are expected to be mechanically strong due to their 
relatively high Young’s modulus 109, 110, and are highly water soluble for rapid dissolution 
in the skin 111. These polysaccharides are degraded by a number of glycosidases, which 
are distributed in all of cell territories: nucleus, cytosol, endoplasmic reticulum, plasma 
membrane, and lysosomes 111 through the endocytosis mechanism with macrophages 112. 
Additionally, disaccharide, trehalose was used for the microneedle matrix material for the 
dissolution enhancer because it has higher solubility in water than high molecular weight 
polysaccharides. A fabrication method for gentle encapsulation of biomolecules was also 
developed with the casting using an aqueous solution that is evaporated at 37oC during 
centrifugation.  
 
4.1.1 Fabrication of dissolving microneedles 
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As the successor to the previous microneedle fabrication methods 28, 94, a method to 
fabricate dissolving microneedles was developed using a micromolding approach that 
faithfully reproduces microneedle structures in an economical manner suitable for scale 
up to mass production. Female master-molds were first prepared out of SU-8 photoresist 
by lithography and reactive ion etching techniques used to create PDMS male master-
structures, shown in Figure 4.1 (a) and (e). These master-structures were then molded to 
make PDMS female molds. PDMS was chosen as the material for master- structures and 
molds because of its ability to conformally coat microstructures and fill micromolds; its 
poor adhesion and flexibility to facilitate separation of microstructures from micromolds; 
and its low cost. 
These micromolds were then used to prepare dissolving microneedles by solvent 
casting with aqueous solutions of CMC and amylopectin or the mixture with trehalose. 
However, simply filling molds with a polysaccharide solution and then drying produced 
weak needles, probably due to structural voids left within the microneedle matrix after 
water evaporation. To avoid this problem, we developed a modified casting method in 
which the CMC solution was first concentrated by evaporation under vacuum (i.e., -50 
kPa) or heating (i.e., 60-70oC) to produce a highly viscous solution that minimized water 
content, but was still fluid enough to fill the mold. We found that an aqueous CMC 
solution with a viscosity of 4.5x105 cP (measured with a Couette viscometer at 1/s shear 
rate at 23oC) met these criteria. In case of amylopectin, the initial solvent removal was 
carried out at elevated temperature (i.e., 60-70oC) rather than just under vacuum, because 
amylopectin has poor water solubility at room temperature. 
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Concentrated polysaccharide solution was then cast into micromolds and dried 
completely by centrifugation at 37oC. The elevated temperature increased the speed of 
evaporation and the centrifugation continuously compressed the mold contents, which 
minimized void formation during drying. This modified casting method was effective to 
reproduce polysaccharide microneedles having the same dimensions as their master-
structures, as shown in Figure 4.1 (b), 4.1 (C), and 4.1 (f) for CMC, amylopectin, and 
CMC/trehalose microneedles, respectively. A similar approach was used to make 
microneedles out of BSA in Figure 4.1 (d), which is a model for making needles out of 
pure drug, rather than encapsulating drug within a polysaccharide matrix.  
As an alternative approach, we tried using high viscosity CMC (1.5 – 3 x 103 cP for 
a  1% aqueous solution at 25oC) as the matrix material, but found that it required much 
more water to be solubilized compared to the ultra-low viscosity CMC used above. As a 
result, the high viscosity CMC took longer to dry and produced deformed microneedles 
that shrank substantially during drying and were mechanically weak. 
Different drug delivery scenarios were addressed by selectively encapsulating drug 
within microneedles, within the microneedle device backing layer, or within both. To 
encapsulate drugs within the polysaccharide matrix, we simply mixed the drug into the 
polysaccharide solution before casting into the molds. To selectively encapsulate within 
the microneedles and not in the backing layer, a smaller volume of drug-polysaccharide 
solution was cast into the holes of the micromold to form the microneedles. After wiping 
off excess solution from the micromold surface, a polysaccharide solution without drug 





Figure 4.1 Microneedles for transdermal drug delivery. (a) Microneedle master-
structure (600 µm in height and 300 µm wide at base). Dissolving microneedle made 
out of (b) CMC, (c) amylopectin and (d) BSA with (a) master-structure; (e) 
Modified microneedle master-structure. (f) Dissolving microneedle made out of 




To selectively encapsulate within the backing layer and not in the microneedles, a 
similar two-step process was carried out, in which the drug was only added to the 
polysaccharide solution applied to the micromold during the second step. Drying of the 
complete, integrated system or just the backing layer during the second step required 1 to 
2 h, whereas drying of just the microneedles during the first step took approximately 30 
min. These process times varied depending on materials and processing conditions. 
 
4.1.2 Mechanical properties of dissolving microneedles 
The design of dissolving microneedles is governed by a number of interdependent 
materials and fabrication constraints, one of which is the need for microneedles to have 
sufficient strength to insert into the skin without mechanical failure. For this question, 
microneedle mechanical properties were therefore measured and simulated as a function 
of microneedle material composition and geometry, and then insertion of optimized 
microneedles into skin was visualized. 
 
4.1.2.1 Measurement of microneedle failure force 
The mechanical behavior of CMC microneedles with a conical shape was first 
measured. As shown in Figure 4.2 (a) by the black circle data points, the force-
displacement curve (which is analogous to a stress-strain curve) exhibited an initial 
increase in force with displacement, followed by a discontinuity at a force of 
approximately 0.1 N/needle. This is interpreted as the point of microneedle failure, which 
is consistent with previous studies 28. Moreover, microscopic examination of the 
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microneedles showed little deformation before this failure point and showed 
microneedles bent up to 90º starting approximately half way up the shaft after this failure 
point, which is consistent with failure by buckling. 
 
Displacement (mm)













































Figure 4.2 Mechanical behavior of dissolving microneedles. Force measured as a 
function of microneedle displacement while pressing against a rigid surface. (a) 
CMC and PLA microneedles having conical and pyramidal geometries and (b) 








Figure 4.3 SEM images of the deformation of CMC pyramidal microneedles loaded 
with each maximum force of 0.05, 0.1, 0.3, 0.5, 1, and 2 N/needle.  
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For comparison, PLA microneedles having the same geometry showed a similar 
curve but demonstrated a five-fold greater failure force of 0.5 N/needle (black diamonds 
in Figure 4.2 (a)). Previous work 28 has shown that conical PLA microneedles similar to 
those used in this study have a failure force more than 3 times greater that the force 
needed for insertion into the skin, which indicates that these conical PLA microneedles 
are suitable for skin insertion without breaking 28. Given that the conical CMC 
microneedles are 5 times weaker than their PLA counterparts, this analysis suggests that 
the conical CMC microneedles are too weak to insert into the skin.  
Because microneedle geometry affects mechanical strength, pyramidal 
microneedles made of CMC and PLA were examined to investigate the difference from 
the different geomtery. In contrast to conical microneedles, pyramidal microneedles did 
not show a distinct transition point indicating failure over the range of conditions tested. 
Microscopic examination of pyramidal microneedles showed a progressive deformation 
of the microneedles, starting near the tip and moving downward with increasing force as 
shown in Figure 4.3, but never showed a catastrophic buckling event at a single point of 
failure. This progressive deformation is consistent with the continuous force-
displacement curve shown in Figure 4.2. The reason for the different behaviors of conical 
and pyramidal microneedles may have to do with the larger aspect ratio and the smaller 
cross-sectional area of conical microneedles.  
To further study the effect of microneedle composition on mechanical strength, the 
mechanical behavior of pyramidal microneedles having the same geometry was measured 
for microneedles made of CMC, PLA, amylopectin, a 20/80 wt% mixture of BSA and 
CMC, and 100% BSA. As shown in Figure 4.2 (b), these five pyramidal microneedles all 
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showed similar mechanical behavior, although the choice of material influenced the 
microneedle strength (i.e., amount of deformation). The materials can be ranked from 
strongest to weakest as: PLA, amylopectin, CMC/BSA, BSA, and CMC. Amylopectin 
microneedles were stronger than CMC microneedles, which can be explained by the 
higher Young’s modulus of amylopectin (4.5 GPa, ref) compared to CMC (1 GPa). CMC 
and CMC/BSA microneedles were designed to simulate a CMC microneedle 
encapsulating a model protein and a microneedle made completely of a model protein, 
respectively. These two microneedles designs had similar mechanical strength, both of 
which were greater than for pure CMC microneedles. In this case, encapsulation of a 
model protein increased microneedle mechanical strength, but this is unlikely to be true 
in all cases. Other encapsulated drugs may decrease microneedle strength.  
 
4.1.2.2 Simulation of microneedle failure force 
To better interpret these experimental results, the mechanical behavior of 
microneedles was simulated to predict the critical buckling load. As shown in Table 4.1, 
the CMC microneedles with a conical geometry (800 µm length and 200 µm base 
diameter) have a predicted failure force of 0.10 N and the PLA microneedles with the 
same geometry have a predicted failure force of 0.51 N, which is in excellent agreement 
with experimental measurements shown in Figure 4.2 (a). The pyramidal microneedles 
(600 µm length and 300 µm base width) made of CMC and PLA have predicted failure 
forces of 1.8 N and 8.9 N, respectively (Table 4.1). The 18-fold increase in critical 
buckling load for these pyramidal microneedles compared to the conical microneedles is 
also consistent with experimental measurements. However, this model accounts only for 
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buckling and does not account for the progressive deformation observed experimentally 
at smaller forces. 
 
 
Table 4.1 Simulated critical buckling load, Pcr of CMC and PLA microneedles as a 
function of microneedle shape, length and base width/diameter. 
Conical (800 µm Length) Pyramidal (600 µm Length) Conical (600 µm Length) 
Diameter 
(µm) 
Pcri (N) Base 
(µm) 
Pcri (N) Diameter 
(µm) 
Pcri (N) 
CMC PLA CMC PLA CMC PLA 
50 0.0004 0.0020 50 0.0020 0.0102 50 0.0007 0.0035 
75 0.0019 0.0096 75 0.0087 0.0435 75 0.0034 0.0171 
100 0.0061 0.0307 100 0.0255 0.1271 100 0.0109 0.0546 
200 0.1021 0.5105 200 0.3639 1.8194 200 0.1815 0.9076 
300 0.5266 2.6329 300 1.7798 8.8899 300 0.9362 4.6808 
400 1.6813 8.4064 400 5.5223 27.6113 400 2.9889 14.9447
600 8.6032 43.0158 500 13.3433 66.7164 500 7.3438 36.7191
800 27.3415 136.7075 600 27.4795 137.3976 600 15.2945 76.4725
 
 
The above comparison involved longer and thinner conical microneedles versus 
shorter and wider pyramidal microneedles. To make a comparison that isolates the effect 
just of microneedle shape, failure force for microneedles of 600 µm length and 300 µm 
base width/diameter was predicted to be 0.93 N and 4.7 N for conical microneedle made 
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of CMC and PLA, respectively, which is almost two-fold smaller than the corresponding 
predictions for pyramidal microneedles (Table 4.1). It is therefore concluded that 
pyramidal microneedles are stronger, probably due to their larger cross-sectional area at 
the same base width/diameter.  
Examination of Table 4.1 for each microneedle design as a function of base 
width/diameter also shows that increasing base dimensions (i.e., decreasing aspect ratio) 
increases needle strength. Thus, using pyramidal microneedles with a small aspect ratio 
can provide added mechanical strength for mechanically weak biomaterials like CMC. 
However, microneedles with an aspect ratio that is too small will also have poor insertion 
due to fabrication difficulties to make a sharp tip and insertion difficulties to force the 
rapidly widening needle shaft into the small hole made in the skin by the needle tip.  
 
4.1.2.3 Microneedle insertion into skin 
Guided by the expectation that pyramidal CMC microneedles with an aspect ratio 
of two should be strong, arrays of these needles were inserted into pig cadaver skin and it 
was found that 100-needle arrays of microneedles were inserted reliably into the skin 
using the gentle force of a thumb. The back side of a representative microneedle array 
made of transparent CMC is shown in Figure 4.4 (a), with its microneedles embedded in 
the skin. After removing the microneedles from the skin after just 3 s, the tips had already 
begun to dissolve (Figure 4.4 (b)), indicating the onset of rapid dissolution in the skin. 
Next the skin was treated with a dye that selectively marks sites of skin penetration and it 
was found that typically all microneedles in the array inserted into the skin, as shown in 
Figure 4.4 (c).  
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Histological examination of skin pierced with microneedles showed penetration 
depths of approximately 150 – 200 µm, which corresponded to insertion across the 
stratum corneum and viable epidermis and into the superficial dermis of the skin, as 
shown in Figure 4.4 (d). The microneedles used in this experiment measured 600 µm in 
length, which means that just one-fourth to one-third of the microneedle shaft penetrated 
into the skin. This can be explained by deformation of the skin’s surface that is known to 
occur during microneedle insertion due to the skin’s viscoelasticity 113. The relatively 
wide base (i.e., 300 µm) and small aspect ratio (i.e., 2) of the pyramidal microneedles 
contributed to this incomplete insertion. Further optimization of microneedle geometry, 
such as aspect ratio, tip sharpness, and spacing between microneedles, and microneedle 
material may increase the depth of insertion. However, partial microneedle insertion 

















Figure 4.4 Imaging microneedle insertion into pig cadaver skin. (a) View of the 
backside of a CMC microneedle patch onto the surface of the skin. (b) CMC 
pyramidal microneedles after insertion into the skin for 3 s. (c) Skin stained with 
red tissue-marking dye to identify the sites of needle penetration after insertion of 
CMC pyramidal microneedles. (d) Cross-sectional image of H&E-stained skin at a 






4.1.3 Release of model drugs from dissolving microneedle patches 
By loading drug into dissolving microneedles in different ways, we were able to 
design systems that can achieve either bolus or extended drug release from a microneedle 
patch. To achieve bolus release, drug was selectively incorporated into the microneedles 
themselves and not into the backing layer. In this way, it was hypothesized that 
microneedles can be inserted into the skin and release the encapsulated drug during their 
rapid dissolution. The rate of release in this scenario is controlled largely by the 
microneedle dissolution rate. A limitation is that the total dose that can be administered is 
small, because microneedles each contain on the order of 25-60 µg of matrix material and 
typically just a fraction of the microneedle matrix can made of drug in order to maintain 
microneedle mechanical strength. Thus, bolus delivery from a microneedle patch 
containing a few hundred microneedles is likely to be limited to less than 1 mg of drug.  
To administer larger drug doses as an extended release over at least hours of time, 
drugs are incorporated into both the microneedles and the backing layer or, alternatively, 
just the backing layer. This permits much larger doses to be administered, because the 
backing layer can be large (e.g., 10 - 100 mg) and can be loaded with larger fractions of 
drug, because backing layer mechanical properties have fewer constraints. In this 
scenario, it was hypothesized that drug can diffuse over time from the drug reservoir in 
the backing layer and into the skin through the transdermal pathways created by the 
dissolving microneedles. In this way, the backing layer acts as a drug source similar to a 






To test hypothesis regarding bolus release from drug-loaded, dissolving 
microneedles, a model drug, sulforhodamine B was selectively encapsulated, in 
pyramidal CMC microneedles. As shown in Figure 4.5 (a), red-colored sulforhodamine 
was encapsulated within each microneedle, but the bottom portion of each microneedle 
and the backing layer did not contain sulforhodamine.  After inserting sulforhodamine-
loaded microneedles into pig cadaver skin and then removing them after 5 min, 
inspection of the skin surface showed an array of red spots corresponding to the sites of 
each microneedle insertion, as shown in Figure 4.5 (b). These spots could not be wiped 
off by cleaning the surface of the skin and are therefore interpreted as sulforhodamine 
deposited within the skin after microneedle dissolution.  
This interpretation is confirmed by histological sections shown in Figure 4.5 (c), 
which show deposition of sulforhodamine within the skin at the sites of microneedle 
penetration after 5 min. The microneedle insertion depth was approximately 150 to 200 
µm, which is in agreement with Figure 4.4 (d). The width of each hole was 
approximately 100 µm (Figure 4.5 (b)), which is similar to the microneedle width at a 
distance of 150 to 200 µm up the shaft from the tip. To supplement this information, 
Figure 4.5 (d) shows a lower-magnification histological section of skin 1 h after insertion 
of bolus-delivery microneedles. In this case sulforhodamine is not located just at the sites 








Figure 4.5 Dissolving microneedles of bolus delivery into skin. (a) CMC pyramidal 
microneedles encapsulating sulforhodamine B within the microneedle shafts, but 
not in the backing layer. (b) Skin surface showing sulforhodamine delivered into the 
skin by insertion of the microneedles shown in part (a) for 5 min imaged by 
brightfiled microscopy. (c) Cross-sectional histological image of skin at the 
penetration site of 2 adjacent microneedles shown in part (a) inserted for 5 min and 
imaged by brightfield (c1) and fluorescence (c2) microscopy. (d) Cross-sectional 
histological image of skin pierced by an array of sulforhodamine-containing 
microneedles for 1 h and imaged by an overlay of brightfield and fluorescence 




Figure 4.6 Dissolution kinetics of microneedles after insertion into skin. (a) CMC 
pyramidal microneedles before insertion and (b) 10 sec, (c) 1 min, (d) 15 min, and 
(e) 1 h after insertion into pig cadaver skin. 
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To generate a better understanding of the kinetics of bolus release from dissolving 
microneedles, we imaged the microneedle dissolution process after insertion into skin for 
different lengths of time. As shown in Figure 4.6, the tips of microneedles dissolved 
within 10 s (Figure 4.6 (b)), half of the microneedle height disappeared within 1 min 
(Figure 4.6 (c)) and two-thirds disappeared within 15 min (Figure 4.6 (d)). After 1 h, the 
microneedles were fully dissolved (Figure 4.6 (e)). These kinetics could be altered by 
changing microneedle geometry and matrix material. It is also worth noting that even 
though microneedles did not penetrate to their full length into the skin, they were 
nonetheless able to fully dissolve, probably due to transport of interstitial fluid from the 
skin up the needle shaft, as discussed below.  
 
4.1.3.2 Sustained release 
To test the hypothesis regarding sustained release, sulforhodamine was 
encapsulated in the backing layer and shafts of pyramidal CMC microneedles (Figure 4.7 
(a)). The microneedle device contained 1 mg of sulforhodamine at a concentration of 10 
wt% (on a dry basis).  These microneedles designed for sustained release could be 
inserted into skin (Figure 4.7 (b)) and histological examination showed release of 
sulforhodamine throughout the skin (Figure 4.7 (c)). 
To quantify sustained release properties in greater detail, we inserted microneedle 
patches into human cadaver skin and measured transdermal flux. Sulforhodamine release 
from CMC microneedle patches exhibited an initial lag time of a few hours, followed by 
steady release for approximately one day (Figure 4.8 (a)). Similar behavior was seen for 
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microneedle patches made of amylopectin, but with slower kinetics. In this case, lag time 
was longer and release took place over a few days (Figure 4.8 (a)).  
These data validate the hypothesis that drug encapsulated within the backing layer 
of a microneedle patch can diffuse out of the patch and into skin. Moreover, they show 
that changing microneedle patch matrix material can alter release kinetics. It is important 
to be able to vary release kinetics based on patch design, because different drugs 
administered for different indications require different release patterns.  
Release rate should also depend on sulforhodamine concentration in the patch. 
Consistent with this expectation, the drug release rate from a patch containing 30 wt% 
sulforhodamine was approximately three times greater than a patch containing 10 wt% 

















Figure 4.7 Dissolving microneedles for sustained release. (a) CMC pyramidal 
microneedles encapsulating sulforhodamine only in the backing layer. (b) Skin 
surface showing sulforhodamine delivered into the skin by insertion of the 
microneedles shown in part (a) for 12 h. (c) Cross-sectional histological image of 
skin pierced by the microneedles shown in part (a) for 12 h and imaged by an 










































































Figure 4.8 Transdermal release profile from dissolving microneedle patches. (a) 
Cumulative release of sulforhodamine encapsulated at 10wt% in the pyramidal 
microneedles and the backing layer of patches made of CMC and amylopectin. (b) 
Cumulative release during the initial release period of sulforhodamine encapsulated 
at 10 wt% or 30 wt% only in the backing layer of CMC patches. Human cadaver 





4.1.4 Drug stability after encapsulation in dissolving microneedles 
Dissolving microneedles were designed to encapsulate sensitive biomolecules using 
a gentle fabrication process. Lysozyme was used as a model protein to assess success of 
this design and the integrity of lysozyme was studied with the measurement of changes in 
secondary structure and enzymatic activity after encapsulation and storage in CMC 
microneedle patches. 
Circular dichroism (CD) analysis of untreated lysozyme compared to lysozyme 
encapsulated within a microneedle patch and then released by dissolution in water 
showed no detectable change in protein secondary structure (Figure 4.9 (a)). Even after 
storage of microneedle patches containing lysozyme for 2 months at room temperature, 
protein structure was unchanged (Figure 4.9 (a)). As a positive control, the CD spectrum 
showed extensive degradation of secondary structure after thermal denaturation (Figure 
4.9 (a)). 
To further test lysozyme integrity, enzymatic activity of lysozyme was measured 
(Figure 4.9 (b)). To make sure that the presence of dissolved CMC after microneedle 
dissolution did not create an artifact, a CMC microneedle containing no lysozyme was 
dissolved in PBS and then mixed with untreated lysozyme. This resulted in no change in 
lysozyme activity (Student’s t-test, p=0.51). To test the effect of encapsulation, 
microneedles containing encapsulated lysozyme were dissolved in PBS and found to 
have no loss of enzymatic activity compared to untreated enzyme (Student’s t-test, 
p=0.28). After two months of storage, lysozyme released from microneedles retained 
96% enzymatic activity, indicating a small loss of activity (Student’s t-test, p=0.03).   
77 
 
From the results of CD and enzymatic activity test, a model enzyme, lysozyme, 
encapsulated in CMC microneedles was not substantially degraded after two months 
storage at room temperature. This stability may be explained by the limited molecular 
mobility in the solid sate that is known to enhance protein stability 87. Additional studies 
are needed to determine if other proteins are similarly stable. For this, the study of human 
growth hormone (hGH) delivery with the dissolving microneedles system was designed 
to assess the efficiency of the dissolving microneedles system as the platform of 

























































Figure 4.9 Protein stability after encapsulation and release from dissolving 
microneedles. (a) Circular Dichroism spectrum of untreated lysozyme (negative 
control); lysozyme encapsulated in CMC microneedles and released by dissolution 
in PBS; lysozyme encapsulated in CMC microneedles and released by dissolution in 
PBS after 2 months storage at room temperature; and lysozyme denatured at 80oC 
for 30 min (positive control). (b) Enzymatic activity of untreated lysozyme (A, 
negative control); lysozyme mixed with dissolved placebo CMC microneedles (B, 
negative control); lysozyme encapsulated in CMC microneedles and released by 
dissolution in PBS (C); lysozyme encapsulated in CMC microneedles and released 
by dissolution in PBS after 2 months storage at room temperature (D). 
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4.2 Human growth hormone delivery results 
Since recombinant gene engineering techniques have enabled the synthesis of 
human growth hormone (hGH), hGH deficient patients have been able to maintain 
required physiologic level of hGH by injection of recombinant hGH. However, they must 
be injected almost daily by trained personnel. Thus, hGH formulated and fabricated in 
dissolving microneedle patches are expected to minimize the need for injections by 
providing an easy and convenient administration technology without the fear and 
inconvenience of needles. Therefore, hGH was selected as a model drug in the study of 
dissolving microneedles for delivering biopharmaceuticals. 
Guided by previous work with dissolving microneedles, the study of human growth 
hormone delivery was designed by examining some questions that must be answered for 
the delivery of hGH. (1) What is the amount of proper time for the administration of the 
microneedle-based patch application? The recovery of skin barrier properties is a critical 
consideration for microneedles patch application, because drug delivery is based on skin 
barrier removal. The microneedle application time will be contingent on the recovery of 
the disrupted stratum corneum. (2) How will the integrity of human growth hormone 
encapsulated in the microneedles be changed during the fabrication process and storage? 
The stability of biopharmaceuticals is directly related to the manufacturing cost of the 
amount of drug required to achieve therapeutic effects. Moreover, the stability time will 
also guide the storage of biopharmaceuticals while they are being transferred from the 
manufacturer to the patients. (3) What is the bioavailability of hGH encapsulated in 
microneedles compared to normal injection methods with hypodermic needles? Similar to 
the question number two, bioavailability is a consideration when determining the choice 
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of the biotherapeutic delivery platform as well as the most important factor in terms of 
the manufacturing cost. (4) Will there be the unfavorable skin reactions when the 
dissolving microneedles system is applied to skin? Contrary to the conventional injection 
method using hypodermic needles, dissolving microneedles leave the drug and the matrix 
material within the upper layer of skin where a responsive reaction might develope when 
the material comes through the skin. This safety problem should be also clearly assessed. 
 
4.2.1 Skin resealing 
As described above, transdermal drug delivery with microneedles is based on the 
removal of the skin barrier; therefore, the skin resealing time must be estimated. The 
kinetics of skin resealing after the insertion of dissolving microneedles was studied using 
a skin impedance measurement. The stratum corneum is a medium of weak electrical 
conduction, because it is a good electrical insulator with almost 106 Ω·cm2 of resistivity 
114. Depending upon the degree of dehydration of stratum corneum or the amount of 
brakeage of the stratum corneum, the impedance between two sites of normal skin and 
disrupted skin will be dramatically changed. Generally, the impedance between the two 
sites decreases sharply with the removal or breakage of the stratum corneum and then 
increases gradually as a function of the recovery of the skin as shown in Figure 4.10. 
The group C (green dots) in Figure 4.10 is the control group representing normal 
skin without the insertion of microneedles. When the skin was occluded at 0 hour, skin 
impedance decreased rapidly and stayed unchanged until the occlusion system was 
removed. After the skin was unoccluded at 24 hour, the impedance increased quickly and 
returned to the normal state before the occlusion. In the group B (red dots), dissolving 
81 
 
microneedles were inserted and immediately removed from the skin, and then the skin 
was occluded. In group B, the skin impedance was almost 10 folds lower than the control 
group (group C) at 1 hour after the insertion and the immediate removal of dissolving 
microneedles. After the removal of the occlusion system at 24 h, the impedance of the 
group B and C increased and returned to normal within 6 hours. 
Unlike group B, group A, in which dissolving microneedles were inserted and 
applied for 24 hours, showed the different behavior in the impedance after 24 h. After the 
removal of the occlusion system at 24 h, group B showed rapid increase in impedance, 
but group A showed a gradual increase 100 folds lower in range than the impedance of 
group B. 
It is possible that group C became hydrated by the occlusion system, causing the 
skin to become more electrically conductive by the addition of strongly dipolar water 
molecules 114, while group B experienced a break in the main electrical insulation layer of 
the skin, stratum corneum, causing the decrease in impedance. Therefore, it is highly 
probable that the lower value of group B impedance compared to group C is the effect of 
the stratum corneum breakage. While the impedance of the group C stayed unchanged 
until the removal of the occlusion system at 24 hour, the impedance of group B increased 
gradually, thus implying recovery of the skin barrier with time.  
However, skin resealing of group A occurred slowly in comparison to the 
impedance measured in group B. It is likely that the dissolved microneedles material, 
CMC remained in the skin and retarded the recovery of the skin barrier. Another result 
also supporting this observation was seen in group D, where dissolving microneedles 
were inserted and immediately removed from the skin in a similar manner to group B. 
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The treated skin was then covered with the backing made of the same matrix material as 
that used in group A, CMC. While this treatment caused material to remain in the skin 
like in group A, the backing in group D was much less dissolved in the skin and a higher 













Figure 4.10 The impedance measurement of the skin after the insertion of dissolving 
microneedles.  
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These differences in the way that skin impedance changes after each treatment 
implies that skin inserted and covered with the dissolving microneedle patch may recover 
stratum corneum slowly and that the dissolving microneedle patch system can be applied 
at least for one day, which may be extended to two days unless side effects such as the 
skin irritation occur. However, this is only the possible application time as estimated by 
the skin resealing time; this does not necessarily mean that microneedle patches should 
be applied for long periods of time due to the fact that microneedles can dissolve within a 
few hours, as estimated in section 4.1.3. Thus, bolus release of drugs with dissolving 
microneedles can likely be completed within a few hours regardless of the skin resealing 
process.  
The delayed resealing process of the treated skin might enable sustained delivery 
using dissolving microneedles. If the backing material of the microneedles is swollen 
with the interstitial fluid from the skin or fluid from the external device, drugs in the 
backing material can diffuse faster, thus allowing transdermal drug administration with 
the dissolving microneedle patch to probably achieve a controlled therapeutic effect of 
the drug for the prolonged time.  
On the other hand, the result shown in Figure 4.10 may be used to prevent infection 
that might occur due to the incompletely sealed skin. Based on the observed changes of 
the impedance, it is believed that the dissolving microneedle patch for bolus release can 
be applied to skin for less than a few hours and then the skin might need to be covered for 





4.2.2. Human growth hormone activity 
We next sought to determine if the processes required for hGH encapsulation in 
microneedles would damage the integrity of hGH. Depending on the process conditions 
used for the formulation of protein biotherapeutics, drugs can exist as various forms (ref) 
such as: covalently or non-covalently linked dimers, higher-order aggregates, and clipped 
forms by degradation due to deamidation. These deteriorated forms of hGH might also 
occur in the fabrication process of dissolving microneedles and would decrease the 
bioavailability of dissolving microneedles encapsulating hGH. Thus, the integrity of hGH 
was investigated with two methods: (1) SDS-PAGE, used widely to identify proteins on 
the basis of molecular weight and (2) Nb2 cell growth analysis for the functional 
structure of hGH, which is relevant to the biological activity of hGH.  
 
4.2.2.1 Electrophoresis (SDS-PAGE) 
SDS-PAGE is used to obtain protein size information. If proteins are cleaved due to 
the reaction in the degradation pathway or if dimeric proteins are formed by the reduction 
of the disulfide bonds, they would appear at a position different from the original 
molecular weight position of the protein.  
Figure 4.11 shows the electrophoresis result of the non-processed and processed 
human growth hormone. The processed hGH is hGH encapsulated with CMC dissolving 
microneedles fabricated using the same process as described in section 4.1 and the non-
processed hGH is the hGH prior to the fabrication process. In Figure 4.11, both non-
processed and processed hGH appeared at the molecular weight position of 22 kDa and 
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the intensity of the bands were almost the same. This shows that the original structure of 
hGH was not damaged by processing, therefore, the centrifugally modified solvent 
casting process used to make hGH microneedles may be compatible with the formulation 





Figure 4.11 SDS-PAGE result of non-processed hGH and processed hGH 
encapsulated within CMC dissolving microneedles. 
 
 
However, a very vague band in the column of the processed hGH was found at the 
molecular weight of the dimer form (44 kDa) of hGH, implying the possibility of forming 
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dimer during the fabrication process. Biosynthetic 22 kDa hGH can exist as the 
noncovalent dimer mediated by the Zn ion 115, or the covalent dimer with disulfide bond 
induced by reducing agents 116. Even though noncovalent dimer is presumed to be the 
major storage form of 22 kDa hGH in the pituitary and was found to be more stable form 
compared to monomeric hGH denaturation in guanidine-HCl 115, it is known to have less 
somatogenic activity than monomeric hGH, e.g. almost one third the potency of 
momomeric 22 kDa hGH 117. Also, the covalent dimer was reported to have about 10% of 
the growth promoting activity of a monomer 117. Thus, the dimeric form of hGH should 
be controlled in the fabrication process, but the result in Figure 4.11 shows that the band 
intensity of the dimer seems to be insignificant. Additional tests such as functional 
activity or pharmacokinetics of hGH should be examined to obtain an overall conclusion 
about the integrity of hGH encapsulated in CMC dissolving microneedles. 
 
 4.2.2.2 Analysis of functional activity of hGH 
The next step for examining the integrity of hGH encapsulated in CMC dissolving 
microneedles was the use of an analytical method to assess the functional activity of hGH. 
The Nb2 cell population method 100, 101, originally used to measure the concentration of 
hGH, was employed to estimate the biological activity of processed hGH.  
Nb2 tumor cells are derived from estrogenized rat lymphoma. While originally 
cultivated in bovine serum-based culture medium, Nb2 cells stop growing and end 
proliferation when transferred to horse serum-based culture medium. Nb2 cells in horse 
serum culture medium resume cell growth upon addition of hGH, and the concentration 
of cells depends on the concentration of hGH added to the medium. Thus, the biological 
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activity of hGH encapsulated in CMC dissolving microneedles can be assessed by 
















Figure 4.12 The increase of Nb2 cell population after the treatment with hGH 
solution made with the reconstitution of hGH encapsulated in CMC dissolving 
microneedles (Yellow group), hGH encapsulated in CMC dissolving microneedle for 
3 months without controlling humidity or temperature (Blue group), non-processed 
hGH (Red group), non-processed hGH mixed with CMC processed with the same 
fabrication method (Green group), and no hGH solution having only processed 
CMC (Black group). With exception of the red group, all groups have the same 
mass proportion of CMC at each hGH concentration (1 hGH: 95 CMC).  
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Figure 4.12 shows the increase in Nb2 cell population stimulated by adding various 
types of hGH solution. Typically, it has been known that the concentration of hGH from 
1 pg/ml to 1 ng/ml has the proportionality to the increase of cell population and the hGH 
concentration higher than 1 ng/ml has the saturation effect of the cell growth 100, 101. The 
red group, the negative control showed the almost 750% population increase due to the 
cell growth stimulation effect of hGH (ANOVA with the replicates at all concentration, 
p=3.85×10-16) and the range of the increased population corresponded well to the value in 
other references 100, 101. However, the black group treated with a solution of only 
reconstituted processed CMC but not hGH, which is used as placebo, showed no effect of 
cell growth, meaning the same population over all concentrations (ANOVA with the 
replicates at all concentration, P=0.29), thus excluding the possibility of growth 
stimulation by CMC. 
The cell populations at each hGH concentration were compared for all groups with 
hGH using the two-factor ANOVA (95% significance) statistical method; (1) Red group 
(non-processed hGH), (2) Green group, in which non-processed hGH is mixed simply 
with the processed CMC, (3) Yellow group, in which hGH is encapsulated in CMC 
dissolving microneedles, and (4) Blue group, in which hGH is encapsulated in CMC 
microneedles for 3 months. According to the two-factor ANOVA result (ANOVA for the 
type of hGH solution, p=9.71×10-6 and ANOVA for the hGH concentration, p=2.05×10-
67), the cell population based on each hGH type was not the same over all concentrations. 
The three ANOVA p values for the two-group comparison of red/green, red/yellow, and 
red/blue over all concentration were 0.02, 0.01, and 9.55×10-7, respectively. Additionally, 
the p value of red/green comparison over all concentration was 0.31 (except 300 pg/ml) 
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meaning that the mixed CMC does not have any stimulation or inhibition effect on the 
cell growth. The p value of red/yellow comparison over all concentrations was 0.0503 
(except 30 pg/ml) meaning that hGH encapsulated in CMC dissolving microneedles 
cause the same increase in population in the red group. Using this statistical analysis and 
the result of Figure 4.12, the integrity of hGH in the blue group (3 months storage) may 
be significantly different from that in the red, green, and yellow groups.  
To determine this, single ANOVA analyses of these 4 groups at the highest 
concentration were performed. At each of 300, 1000, and 3000 pg/ml, red/green/yellow 
group showed the same increase of population (p=0.09, 0.31, and 0.1, respectively). 
However, the comparison of red/green/yellow/blue at each of 300, 1000, and 3000 pg/ml 
suggested that they had different cell population (p=0.0089, 0.0099, and 0.0027). 
Therefore, it is suggested that the processes used to fabricate hGH encapsulating 
microneedles did not damage the integrity of hGH.  
Based on the result of the activity test with Nb2 cells, hGH encapsulated in CMC 
dissolving microneedles still maintained its integrity and biological activity, but an 
approximately 15% reduction of the maximum increase in cell population was found at 
the saturation range, 1000 and 3000 pg/ml, of hGH concentration. Thus, it is highly 
probable that hGH in CMC microneedles loses its integrity partially after 3 months 
storage. However, hGH encapsulating CMC dissolving microneedles in the blue group 
was exposed to air (21% oxygen) with 21-25oC and 35-45% relative humidity conditions 
without controlling these variables. It is expected that the activity loss of hGH 
encapsulated in CMC dissolving microneedles could be lessened using a controlled 
storage protocol, with lower temperature or by vacuum packaging to control humidity. In 
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conclusion, hGH encapsulated in CMC dissolving microneedles did not lose its biological 
activity and it is possible that the processes used to fabricate CMC dissolving 
microneedles may be compatible with the formulation of other sensitive 
biopharmaceuticals.  
 
4.2.3 Pharmacokinetics of human growth hormone 
Dissolving microneedles were designed to replace the administration of drugs using 
hypodermic needles with a painless, sharps-free, and self-administered delivery tool. 
However, these advantages over hypodermic needles can be highlighted when the 
dissolving microneedles system is able to achieve a similar level of bioavailability or 
pharmaceutical effect of the injection method by hypodermic needles. This work 
hypothesized that CMC dissolving microneedles can deliver drugs without loss of 
integrity by breaking the skin barrier and releasing drugs upon the dissolution of the 
microneedles matrix. To verify this hypothesis, it was demonstrated that hGH can be 
encapsulated in CMC dissolving microneedles without integrity loss as shown in Figure 
4.11 and 4.12. Guided by this result, the pharmacokinetics of hGH were studies to assess 
how effectively CMC dissolving microneedles can deliver hGH to the body and to 
determine any difference from the injection method. 
The preliminary result of in vivo delivery of hGH encapsulated in CMC dissolving 
microneedles showed less than 10% of the bioavailability of the subcutaneous injection 
delivery method (data not shown). The reason for this was thought to be the limited 
amount of interstitial fluid available to dissolve microneedle matrix material. To increase 
the dissolution rate, the microneedles matrix material can be formulated with a mixture of 
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polysaccharide and disaccharides. Polysaccharide is the mechanical support material for 
the insertion into the skin and disaccharide is used as the dissolution enhancer, lowering 





Figure 4.13 Summary of hGH formulation and administration. The subcutaneous 
injection of hGH as the positive control (Group 3, Black), hGH formulated with 
only polysaccharide CMC (Group 1, Red for the microneedle administration and 
group 5, Blue for subcutaneous injection of the reconstitution), hGH formulated 
with the mixture of polysaccharide, CMC and disaccharide, trehalose (Group 2, 
Yellow for the microneedle administration and Group 4, Green for subcutaneous 
injection of the reconstitution). Especially, hGH in group 5 was stored for 15 months 
without controlling humidity and temperature after the encapsulation in CMC 
matrix material.  
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It was hypothesized that CMC/trehalose microneedles have higher bioavailability 
than CMC microneedles because CMC/trehalose microneedles dissolve faster in the skin 
and thereby release more hGH during the same period of time. Based on this assumption, 
hGH was formulated with two types of microneedle matrix, CMC and CMC/trehalose 
mixture. The summarized description of hGH formulation and administration in each 
group is shown in Figure 4.13. 
The pharmacokinetics profile of each group is shown in Figure 4.14. The group 1 in 
Figure 4.14 represents the originally designed dissolving microneedles which are made of 
only CMC polysaccharide, which releases hGH by the dissolution of CMC microneedles. 
As shown in Figure 4.14, the serum concentration of hGH of group 1 at the peak time 
between 0.5 and 1 hour was 6 fold lower than one of the subcutaneously injected 
unprocessed-hGH (group 3) (student’s t-test, 95% significance, p=2.258×10-6) and the 
area under the profile of group 1 was approximately 9 fold lower than one of group 3 
(student’s t-test, 95% significance, p=1.41×10-6). Contrary to group 1, hGH in group 2 
fabricated with the mixture matrix of CMC and trehalose showed almost the same but 
just 1.3 fold lower serum concentration than one of group 3 at peak time (student’s t-test, 
95% significance, p=0.15) and the area under the profile of group 2 was 1.5 fold lower 
than that of group 3 (student’s t-test, 95% significance, p=0.0143). For the comparison of 
group 1 and 2, hGH in group 2 showed almost 5 fold higher serum concentration than 
group 1 at peak time (student’s t-test, 95% significance, p=0.0003) and the area under the 
profile of group 2 was 6 fold higher than group 1 (student’s t-test, 95% significance, 
p=1.23×10-5). The area under the profile and bioavailability of all groups are summarized 

































Group 1: processed hGH in CMC MN            
Group 2: processed hGH in CMC/trehalose MN     
Group 3: unprocessed hGH (SC)
Group 4: processed hGH in CMC/trehalose MN (SC)
Group 5: processed hGH in CMC MN (stored) (SC)
 
 
Figure 4.14 Pharmcokinetics profile of hGH in rat serum. Microneedle 
administration of hGH in CMC microneedles (Group 1, n=6), Microneedle 
administration of hGH in CMC/trehalose microneedles (Group 2, n=6), 
Subcutaneous injection of hGH as the positive control (Group 3, n=6), Subcutaneous 
injection of the reconstitution of hGH in CMC/trehalose microneedles (Group 4, 
n=6), and Subcutaneous injection of the reconstitution of hGH in CMC 
microneedles stored for 15 months after the fabrication (Group 5, n=3). MN and SC 




Table 4.2 The applied dose (µg), area under curve (*AUC in hr·ng/ml), and 













Dose (± SE) 148 ± 3 164 ± 13 169 ± 6 167 ± 19 162*** 
Avg. 
AUC (±SE) 20 ± 5 120 ± 11 174 ± 14 181 ± 11 101 ± 28 
BA (±SE) 13 ± 3 71 ± 7 100 ± 8 106 ± 6 61 ± 17 
*AUC was calculated with trapezoid area formula. **BA = (AUCgroup/Dosegroup)/(AUCgroup 0 avg./Dosegroup 0 avg) 
*** Based on the formulation value 
 
 
The difference between the pharmacokinetics profiles of groups 1 and 2 is probably 
a result of the different microneedles matrix materials. To verify this hypothesis, two 
things were examined; (1) microscopic images of the microneedles surface after 24 h 
application and (2) the measurement of the remaining hGH in the system after 24 h 
application.  
The surfaces of CMC microneedles (group 1) and CMC/trehalose microneedles 
(group 2) were imaged using scanning electron microscopy as shown in Figure 4.15. 
While CMC microneedles retained the blunt upper part of the original microneedle shape, 
CMC/Trehalose microneedles almost disappeared, leaving a small amount of bumpy 
surface. Due to the relatively higher solubility property of trehalose over CMC, it is 
probable that the CMC/trehalose mixture matrix could more easily dissolve and thus 
release encapsulated hGH faster than the CMC alone matrix. 
The remaining hGH in group 1 was 69 ± 3 % (±SE) of total amount of hGH before 
application while group 2 was 17 ± 3 % (±SE) of total amount of hGH before the 
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application. Using the bioavailability (BA) information in Table 3.1 and measuring the 
amount of hGH remaining in the system, groups 1 and 2 had 82 % (13 % BA + 69 % 
remaining hGH) and 88 % (71 % BA + 17 % remaining of hGH) of total amount of hGH 
in the system before the insertion. The uncounted part of hGH (18 % for group 1 and 
12 % of group 2) can be explained by the comparison of group 3. In group 3, the total 
hGH dose that was administered rapidly by a hypodermic needle can circulate almost 
immediately to the blood vessels; therefore the drug infusion time is shorter than that of 
group 1 where hGH is released relatively slowly from the microneedle matrix resulting in 
a lower infusion rate. Thus, blood from group 3 will have a more rapid increase of hGH 
concentration while blood from groups 1 and 2 will increase hGH concentration more 
slowly.  On the other hand, blood with a lower concentration of hGH will clear hGH 
more effectively and easily; therefore, groups 1 and 2 may have cleared hGH from the 
body, explaining why there is some hGH unaccounted for thin the measurements 
described above.  
Regarding the bioavailability of hGH formulation, another interesting result was 
observed that may also support this finding. When reconstituted CMC/trehalose 
encapsulating hGH was injected subcutaneously (group 4), the pharmacokinetic profile 
over time of this group 4 was almost the same as that of group 3 (two-factor ANOVA, 
95% significance, p=0.15) and the bioavailability of hGH in both groups was almost the 
same (Student’s t-test, 95% significance, p=0.61). This implies that if the dissolving 
microneedles had less drug remaining in the system after insertion, it may be a successful 
replacement for hGH administration. However, this must be achieved by a perfect 
insertion of dissolving microneedles made out of the mixture of polysaccharide and 
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disaccharide, thus creating high bioavailability comparable to subcutaneous injection. It 
is therefore worth examining this by designing a new geometry of dissolving 
microneedles to be inserted more perfectly into skin, thus enhancing the rate of 




(a)                                                    (b) 
Figure 4.15 SEM images of dissolving microneedles after 24 hours of insertion; (a) 
CMC microneedles and (b) CMC/Trehalose microneedles. 
 
It was also hypothesized that encapsulating drugs in the solid form of dissolving 
microneedles can assist in manufacturing biotherapeutics for extended periods of time 
due to the limited mobility of the molecules when stored in this from 32. To determine 
how long hGH will maintain integrity in dissolving microneedles, hGH encapsulated in 
CMC microneedles was stored for 15 months (group 5) without humidity or temperature 
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control to simulate the storage of normal drugs in the home. hGH in group 5 was 
subcutaneously injected after reconstitution. 
As shown in Figure 4.14, the bioavailability of hGH in group 5 was estimated as 
approximately 60% compared to bioavailability of hGH in group 3. In a previous study 
using SDS-PAGE (section 4.2.2.1) and Nb2 cell population (section 4.2.2.2) to examine 
the integrity of the processed hGH and the pharmacokinetics of hGH, it was seen that 
hGH processed for the fabrication of dissolving microneedles did not lose its integrity, 
and showed that it was similar levels or insignificant changes in parameters from the non-
processed hGH. 
However, after 3 months (Nb2 cell assay) and 15 months of storage 
(Pharmacokinetics), hGH assayed for these showed the lower levels, 85% and 60%, 
respectively. However, since the hGH studied in this work was stored without control 
over the storage conditions, it is highly probable that dissolving microneedles can 
encapsulate biotherapeutics and maintain their integrity for a long periods of time when 
storage conditions are controlled at low temperature and/or low humidity. 
Regarding the stability of the commercialized recombinant hGH, the suggested 
shelf life for freeze-dried hGH is around 2 years with the storage at 2-8oC and the 
reconstituted solution can be stored for around 2 weeks at 2-8oC 118. However, the major 
degradation reactions; deamidation, oxidation, and aggregation were found after the 
storage of freeze-dried hGH in 5 ml vial with a nominal nitrogen headspace (~0.75% O2) 
at room temperature (25oC) over 6 months 119. The freeze-dried hGH with no excipients 
stored under these condition showed around 12% decomposition of hGH by oxidation. It 
was found that even small increase (from 0.4% to 0.75%) of oxygen concenration 
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resulted in almost 2 fold higher degree of oxidation (the molar ratio of oxygen to hGH at 
0.4% oxygen is around 10, which is more than sufficient from a stoichiometric 
viewpoint). Comparing this with hGH encapsulated in microneedles, microneedles 
system, which is exposed to 21% oxygen (air), seems to be able to reduce the oxidation 
by limiting the approach of oxygen molecules to hGH molecules in microneedles. Thus, 
it is probable that the stability of hGH for the long term storage can be improved by 
considering these. 
 
4.2.4 Skin reaction 
Organ systems used for the drug administration will show some functional 
responses to the artificial methods in which some treatments are applied for the 
enhancement of the drug absorption, recognizing those as the invaders and trying to 
regain the normal 38, 120. Because the mechanism of dissolving microneedles is to break 
the skin barrier, stratum corneum, to be dissolved in the skin leaving microneedles matrix 
material, and then to release drug into the body, it is believed that the skin will react 
against the breakage of the skin or the material left inside. To assess the skin reaction 
caused by the insertion of dissolving microneedles, erythema was measured (Figure 4.16) 
by using 0-4 scale with half-point ratings 102 and the surfaces of the skin inserted with 
microneedles were examined as shown in Figure 4.17.  
As expected, the surface of the skin inserted by a hypodermic needle (group 3 and 4 
in Figure 4.16) did not show any symptom suspected for the skin reaction at 24 h when 
the system was removed. The skin of group 3 and 4 was rated as normal over the whole 
time. However, group 1 and 3 inserted with microneedles showed only more reddish 
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color on the surface of the applied skin, but edema (skin swelling) was not identified as 
shown in Figure 4.17. 
In Figure 4.17, the erythema symptom shown in group 1 and 2 decreased rapidly 
for the first 3 hours after the removal of the system at 24 h and it disappeared somewhat 
slowly over time. When 2 days passed after the removal of the system, the skin surface in 
both groups looked almost normal. After 3 days after the removal of the system, the 
surface of the applied skin returned to the normal before the insertion of the system and 
all skin surfaces were rated as normal as shown in Figure 4.16. However, the skin color 
of group 2 at 24 h was more reddish than group 1 and the erythema ratings of group 1 and 
2 over time (Figure 4.16) were different (two-way ANOVA, 95% significance, p=0.001). 
This might be caused by the different microneedle matrix material. In group 2, the 
mixture of CMC and trehalose was used and the dissolution of mixture microneedles may 
be probably faster than CMC microneedles of group 1, resulting the faster clearance of 
microneedles matrix material and thereby the less redness. From the result of Figure 4.16 
and 4.17, dissolving microneedles made out of polysaccharide or disaccharide did not 
cause severe erythema or edema. Even though the skin color was somewhat noticeable at 
the end of the 24 hours application, it started disappearing significantly soon and returned 
as normal skin within 2 days. Thus, it is suggested that dissolving microneedles can be 
used without the unfavorable skin reaction as one of alternatives for the enhanced 

























Group 1: CMC MN encapsulating hGH
Group 2: CMC/TH MN encapsulating hGH
Group 3: SC Injection of hGH




Figure 4.16 Skin erythema rating with 0-4 scale: 0-normal skin, 1-slight, 2-mild, 3-
moderate, and 4-severe (very intense). For the first 24 hours, the skin and the 
system were occluded with the bandaging and the skin was kept unoccluded from 24 
to 96 h with the removal of the system and the bandaging at 24 h. (n ≥ 4 for up to 72 






Figure 4.17 The representative image of the skin surface in the recovery progress 
after the administration of hGH with microneedles (group 1 and 2) or hypodermic 
needles (group 3 and 4). The skin was occluded with the system and the bandaging 
from 0 to 24 h and unoccluded after 24 h. hGH was administered through each skin 
with CMC microneedles (group 1), CMC/trehalose microneedles (group 2), a 
hypodermic needle after the reconstitution (group 3), and a hypodermic needle after 
the reconstitution of CMC/trehalose system (group 4). 
 
 
We checked these skins by visually examining the histological images of them as 
shown in Figure 4.18. The skin of each group at 24 h, 48 h, and 1 week after the insertion 
of dissolving microneedles was sectioned, H&E stained, and viewed with the brightfield 
microscope. Figure 4.18 shows the histological images of the skin of group 1 and 2 at 
three different time points. The insertion sites in the skin at 24 h were easily found, but it 
was difficult to find them with the skin samples prepared for biopsy at 1 week after the 
insertion of microneedles, suggesting that the insertion sites were probably partially 
recovered at 24 h after the removal of the system. The skin samples of group 3 and 4 
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(subcutaneous injection) were found as the same to the untreated skin without noticeable 
features (data not shown), but the skin of group 1 and 2 at 24 h showed an interesting 
feature on the sites inserted presumably by dissolving microneedles as shown in Figure 





Figure 4.18 The histological images of the skin inserted by CMC microneedles 
(Group 1 – a, b, and c) and inserted by CMC/trehalose microneedles (Group 2 – d, e, 
and f) at 24 h (a and d), 48 h (b and e), and 1 week (c and f) after the insertion and 
the removal of dissolving microneedles 24 h. 
 
Some features in which the processes probably related to the skin recovery were 
occurring intensively was found at the insertion sites of the skin at 24 h in both group 1 
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and 2 as shown in Figure 4.19 (g-h). A number of dark ball-shape structures were 
observed specifically at the site inserted with dissolving microneedles. This may probably 
be the cellular infiltration phenomenon which is the migration of macrophages associated 
with inflammations 121 to the skin sites of microneedles insertion. In Figure 4.18, it is 
thought that basophil granulocytes, one type of white blood cells, migrated to the 
insertion site and degranulated to release substances contributing to inflammation 
because basophils show dark blue color after H&E staining and the degranulating form at 
the upper layer of the damaged stratum corneum. The reddish color on the skin surface is 
likely to be the result of the increased flow of blood near the insertion site for the 
migration of basophils. Thus, it is highly probable that the inflammatory response 
occurred against the insertion of dissolving microneedles and would trigger the skin 
healing. These might be helpful features to prevent the infection problem that might 












Figure 4.19 The magnified images (g-l) of the inserted sites of the skin in group 1 
and 2 at 24 h 
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4.3 Micro skin ablation results 
Various types of transdermal drug applications are designed to achieve therapeutic 
effects of drugs, which are not possible using the conventional transdermal patch, by 
disrupting integrity of the skin barrier, stratum corneum such as chemical enhancer 57, 
ultrasound 70, microenhancer array 24, tape stripping 89, and microneedle 20. Thermal 
energy has also been used to remove stratum corneum for monitoring glucose 122 or 
delivering drugs 21, 91. However, none of those based on thermal energy completely 
remove stratum corneum selectively and they ablate skin with the longer operation time 
than 1 ms. 
We hypothesized that an extremely rapid pulse of thermal energy onto the skin can 
remove stratum corneum selectively without damaging deeper skin tissue, and allowing 
hydrophilic and macromolecular biotherapeutics to be delivered through the ablated skin. 
In this study, we (1) designed and developed the micro skin ablation (MSA) device to 
work on a timescale of micro second, (2) assessed the ability of the MSA to completely 
remove stratum corneum selectively, and (3) demonstrated increased skin permeability of 
hydrophilic or macro molecular compounds after treatment with the MSA. 
To study this hypothesis, some important factors were considered. First, how much 
energy is necessary to ablate stratum corneum and at what speed should it impact the 
skin? The effect of thermal energy contact on skin have been reported for a long time, but 
most were skin burns or skin tissue damage due to a relatively long exposure to thermal 
energy. The rapid impact of ablation energy on skin will be the critical point in the design 
of the MSA device to achieve the selective removal of skin barrier. 
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Next, what type of energy source can be used to generate and transfer the ablation 
energy to the skin rapidly? This system should be able to transfer enough ablation energy 
to the skin within a specified amount of time to prevent deeper skin tissue damage. Using 
these specifications, a micro skin ablation (MSA) device based on arc discharge 
phenomenon was developed to generate energy impact and transfer it to the skin. When 
an arc is generated, it rapidly increases the temperature of the medium in which the arc 
occurs and a buildup of pressure follows after the discharge. Since arc discharge 
phenomenon can release thermal and mechanical energy very quickly 103, it is probable 
that enough energy to ablate stratum corneum can be sufficiently produced and then 
rapidly transferred to the skin. 
Finally, it must be determined how much drug can be delivered using the MSA 
system. The MSA system will achieve therapeutic effect by passive diffusion of drug 
from the drug matrix into the skin in a manner similar to other conventional transdermal 
patch applications. The amount of diffused drug will be determined using parameters that 
control the rate of diffusion, including the area of diffusion, molecular weight of the drug, 
and the drug concentration in the matrix, but not with stratum corneum. In this study, the 
removal of stratum corneum by the MSA was controlled because the most important 
parameter will be the area of ablated skin through which drug can diffuse. Thus, it was 
important to control both the surface area and depth of stratum corneum removal. This 
could be achieved using two masking systems to guide the energy impact properly, 
followed by assessment of the permeation of drugs using Franz cell systems for in-vitro 
drug release experiments with two model compounds, sulforhodamine and Texas Red 
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BSA; which represent a small molecular weight drug and a high molecular weight 
biotherapeutic, respectively. 
 
4.3.1 Fabrication and characterization of arc-generating device  
Because the rapid impact of thermal energy on skin is a key to the success of the 
MSA system, arc discharge was considered to be a good model for the energy source of 
the MSA system. The arc generating system used to create the energy impact was 
fabricated by modifying the laminated gas generator actuator system 103. The entire MSA 
system was designed to have two main parts; (1) a power supply circuit with the 
controller to provide electrical energy and (2) a microchamber to convert the provided 
electrical energy to ablation energy as shown in Figure 4.20. Two electrodes on the 
bottom and the top of the microchamber are connected to the circuit with discharging 
capacitors to supply electrical energy. All parts of microchamber shown in Figure 4.20 
were fabricated with laser micromachining and lamination techniques so that the mass 
production of MSA system would be possible as a cartridge system combined with the 
additional electrical power supplier. 
To generate the ablation energy, the microchamber was filled with PBS, which is 
used as the conductive medium necessary to induce arc discharge phenomenon in the 
microchamber, and then the electrical energy was supplied from the circuit to two 
electrodes. The MSA device was tested by adjusting the voltage of the charge to the 
capacitor in the circuit from 100 V to 200 V and 150 V was experimentally determined 
and optimized as the threshold voltage range to obtain the reliable energy impact so the 
electrical energy with around 145-150 V was charged to capacitors in the circuit. When 
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two electrodes in the microchamber get connected to the circuit by applying the pulse to 
MOSFET, arc discharge occurred between two electrodes and then the energy medium 
was ejected from the MSA microchamber as shown in Figure 4.20 (d).  
 
 
                               (a)                                                                                (b) 
 
                   
                                (c)                                                                               (d) 
Figure 4.20 The microchamber for micro thermal ablation (MTA) in which arc 
discharge phenomenon occurs. (a) cross-sectional image of microchamber, (b) the 
disassembled parts of microchamber, (c) the laminated MSA device (backing, 
electrode, and chamber layers), and (d) the energy jet ejected from MSA device 104. 
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During arc discharge, the voltage drop across the electrodes was measured as 
shown in Figure 4.21, implying that the stored electrical energy to the capacitor was 
consumed to generate arc discharge between two electrodes. In Figure 4.21, the voltage 
dropped drastically within less than 0.1 ms and decreased gradually until 1.3 ms. This 
means that arc discharge was completed in 0.1 ms and the generation of thermal energy 
stopped after approximately 1.3 ms. While MOSFET in the circuit remains ON for the 
pulse length, 1.5 ms, the electrical energy from the capacitor was supplied to the 
microchamber. Even though arc discharge is completed in 0.1 ms, the MSA device still 
has some conductive path in the microchamber, probably due to salt particles and leakage 
in the circuit through which the capacitor tries to discharge, showing the gradual voltage 
drop. If the length of pulse applied to MOSFET is reduced like 0.5 ms, the sharp voltage 
drop might be seen without the gradual decrease. However, in case of the reduced pulse 
length, the variation from device to device was found and the discharge process did not 
start with the reduced length of pulse because MSA system is required to have enough 
time to start the discharge process. The peak voltage around 135 V in Figure 4.21 is the 
voltage across the microchamber, Vhigh (145 V) – Vlow (10 V), as it has the power supply 
on one side and MOSFET on the other side of the microchamber (Figure 3.5 (b)). 
This time characterization as shown in Figure 4.22 was supported by the 
measurement of force generated by jet following arc discharge phenomenon. Figure 4.22 
is a sample result of the measured force according to the operation time. When the MSA 
device started the discharging process with MOSFET ON, the first peak of force lasted 
for approximately 0.1 ms and the rest part after 0.1 ms was fluctuated over time, then 
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became still. It is thought that the first peak of force was due to arc discharge and the 





Figure 4.21 Power characteristics of MTA system during the arc generation process. 
The total energy (in blue) released by arc discharge is estimated with the change of 
voltage (in red) and current (in pink) across electrodes in the microchamber 104. 
 
 
This short duration of the energy impact was the desired feature of the MSA system 
because the time required for the energy impact to the skin will be determined mainly by 
the duration of the thermal energy source. Moreover, the total power consumed by the arc 
discharge generating process in Figure 4.21 was calculated with the value of 
111 
 
approximately 2.7-3.3 kW. This energy is not all converted into the required amount of 
the skin ablation energy, but the power released from this system is almost 2 fold higher 
than the commercialized laser ablation devices using the power ranging up to around 1.5-
1.8 kW 19, 90. From the viewpoint of this, arc discharge is thought to be the appropriate 






Figure 4.22 The measurement of force (in yellow) generated by arc discharge and 





4.3.2 Design of skin ablation function of arc-generating device 
Guided by the rapid generation and extinction of ablation energy with arc discharge, 
it is believed that the function of MSA is feasible with this arc discharge generating 
device. Four skin ablation scenarios were designed in Table 3.1: thermo-mechanical 
ablation without or with the localization and thermal ablation without or with localization.  
First, pig cadaver skin was exposed directly to the nozzle of the microchamber in 
order to examine whether the MSA system can remove stratum corneum selectively. 
Figure 4.23 shows histological images of pig skin samples ablated thermo-mechanically 
without and with the localization by using the windows mask. Both skin samples were 
found to have the removal of stratum corneum, implying that it was successfully 
selectively removed by the energy impact generated by the MSA system. Moreover, the 
skin sample (Figure 4.23 (b)) locally ablated with the windows mask had the multiple 
ablation sites while the skin sample ablated without the mask (Figure 4.23 (a)) shows a 
relatively larger area of skin ablation. As the purpose of the windows mask is to allow the 
MSA system to control the ablation area and thus achieve the minimized spots of ablation 
that are necessary for allowing skin to heal easily and make the treated areas cosmetically 
invisible. 
However, arc discharge is followed by various physical phenomena due to the 
sudden release of high level of thermal energy. The thermal energy generated in the 
microchamber can be consumed to increase the temperature of medium filled in the 
microchamber or to melt the layer parts of the microchamber. In result, an unfavorable 
object might be created in the microchamber by thermal energy and it can be also ejected 
along the ablation energy as shown in Figure 4.23 where the black debris is deposited 
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onto the ablation site of the skin. Therefore, the solid masking system as shown in Figure 
4.24 was designed for two issues; (1) to avoid depositing debris from the microchamber 
onto the skin and (2) to make mechanistic comparisons between the thermal effect or the 





Figure 4.23 Histological images of pig cadaver skin samples ablated thermo-
mechanically (a) without and (b) with the windows mask (SC: stratum corneum, 
EP: viable epidermis, and DE: dermis). 
 
 
The solid mask is inserted between the nozzle of the microchamber and the surface 
of the skin as shown in Figure 4.24 (a). Any other effect of arc discharge can be blocked 
and only thermal energy released by arc discharge can be transferred through the solid 
mask. To control the ablation area, the use of the windows mask was also designed with 
the combination of solid mask as shown in Figure 4.24 (b). It is placed under the solid 
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mask to guide the impact of thermal energy through holes in the windows mask. It is 
expected that the area of thermal skin ablation can be controlled and localized with these 





Figure 4.24 Schematic description of thermal skin ablation system with arc 
discharge. (a) No localization only with solid mask and (b) Localization with solid 
and windows mask. 
 
 
4.3.3 Thermal energy characterization for thermal skin ablation 
Arc discharge was found to generate relatively high level energy within 0.1 ms. It 
must then be determined how much energy for thermal skin ablation is generated and 
115 
 
transferred onto the skin. The temperature of thermal energy transferred to the skin was 
measured to characterize thermal energy by using temperature indicating papers 
described in the method section 3.3.2.1, which shows the black color of the background 
through the melted polymer after the contact of thermal energy at the designated 





Figure 4.25 The color change of temperature indicating paper after the operation of 
thermal skin ablation system. The temperature measurement was performed with 
different kinds of metal solid masks but having the same thickness (25 µm); 
titanium, nickel, and tungsten, the thermal conductivity of which were 22, 91, and 




In Figure 4.25, 25 µm thickness nickel, tungsten and titanium sheets were used as 
the solid mask covering temperature indication paper. The available maximum 
temperature which can be detected was 290oC. In the case of the titanium solid mask, the 
black color of the background support was shown, meaning that the temperature of 
thermal energy transferred through the titanium mask reached 290oC, but it had the 
relatively smaller area of the black color due to low thermal conductivity. Nickel and 
tungsten masks showed the larger black area because they allowed a greater amount of 
thermal energy than the titanium mask due to higher conductivity. 
According to the previous study 123 regarding the heat effect on skin permeability, 
the transdermal flux of drug was increased to 1000 fold higher when the skin was 
contacted with a hot object at approximately 300oC. The temperature of thermal energy 
transferred through the tungsten solid mask showed the color change at 290oC as shown 
in Figure 4.25. From these results, it was expected that the thermal energy released from 
arc discharge may greatly increase the transdermal flux of drugs. The temperature of the 
thermal energy applied to the skin surface can be controlled by the thickness and thermal 
conductivity of the solid metal masks. Nickel has been shown to cause skin allergies in 
some people; therefore, tungsten was selected for the solid mask in subsequent 
experiments. 
Because of the limited availability of temperature indicating paper for temperatures 
higher than 290oC, a more precise measurement of thermal energy was necessary. 
However, it was found that the minimum temperature of thermal energy contacting the 
skin was around 290oC123, which can enable a significant increase in drug flux, so we 
simulated the temperature profile from the outer surface of the solid mask to the 
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epidermis layer in order to estimate the penetration of thermal energy from arc discharge. 
This was especially important for determining how deeply thermal energy can penetrate 
into the skin during the MSA operation time of 0.1 ms. 
In section 4.3.1, the amount of stored electrical energy in the system was calculated 
to be about 4.6 J using the measurement of voltage drop (Figure 4.21). Using the 
assumption that this energy was completely consumed to increase the temperature of the 
medium in the microchamber, the temperature of the medium was computed to be 




E: 4.6 J  
Mass of water in the microchamber, m: 1 mg 
∆twater: 75oC (from room temperature to boiling point at 1 atm) 
Specific heat of water, Cp: 4.186 J/g·oC at 1 atm 
Specific heat of vapor at 1 bar and 100oC, Cp,vap : 2.04 J/g·oC at 1 atm 
Heat of vaporization, ∆Hvap: 2255 J/g at 1 atm 
 
By using the computational result for the temperature of the ejected medium, the 
temperature profile of each layer from the solid mask to the epidermis layer was 
simulated as shown in Figure 4.26, using the assumptions that (1) the outermost surface 
of the layers contacts the medium at 1100oC, (2) physical properties of each layer are 
constant over the range of temperature, (3) each layer contacts another without any gap 
between layers, (4) the skin layers can maintain integrity over the range of temperatures, 
and (5) one-dimensional transient semi-infinite model applies.  
Based on these assumptions, the temperature profile of each ablation scenario was 
simulated in Figure 4.26. The green and red line in three graphs (a, b, and c) of Figure 
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4.26 represent the temperature profile of each layer at 100 µs and 1 ms contact time with 
hot medium ejected from the microchamber, respectively. In the case of 100 µs contact 
time, the temperature at the junction of stratum corneum and viable epidermis layer was 
the same as body temperature, but increased to approximately 200oC after 1 ms contact 
time as shown in Figure 4.26 (d). This means that contact times greater than 100 µs might 
be sufficient transfer a significant amount of thermal energy to the skinm resulting in 
deeper skin tissue damage. However, because it was assumed that all electrical energy is 
converted into thermal energy and the temperature of hot medium (1100oC) is already 
fixed at the start of the contact time, the critical operation time without deeper skin 
damage might be longer in practice and the real temperature profile for all layers might 
be lower than the result shown in Figure 4.26.  
Interestingly, stratum corneum has the lowest thermal conductivity among all layers 
so that the transfer of thermal energy from the microchamber is most hindered in this 
region and the temperature drops significantly. Therefore, if the debris is not ejected from 
the microchamber, it would probably ablate the skin selectively without the solid mask as 
shown in Figure 4.26 (a).  
Comparing graphs (b) and (c) in Figure 4.26, the titanium windows mask 
significantly decreased the temperature of thermal energy penetrating into stratum 
corneum during the contacting time from 10 to 100 µs, but it became a less effective 
insulation mask at the longer contacting time, which was greater than 100 µs. Although 
the thermal conductivity of titanium is 8 fold lower than the tungsten used for the solid 
mask, it does not effectively perform the heat insulation function for longer times. Instead, 
if the polymer thin film can be used as the windows mask, the insulation function of the 
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windows mask will be more effective because the thermal conductivity of polymer is 
usually 103-104 times lower than metal 105. However, the choice of polymer film should 
be considered in regard to the safety issues and/or the possible clogging of windows that 




Figure 4.26 Simulation of the temperature profile from the solid mask to viable 
epidermis layer in each case. The upper schematic is the summarized description of 
each case (SM: 25 µm thick tungsten solid mask, WM: 25 µm thick titanium 
windows mask, SC: human stratum corneum, and VE: human viable epidermis). 
The shaded region in three graphs (a, b, and c) represents stratum corneum; Case 1: 
SC-VE (graph a), Case 2: SM-SC-VE (graph b), and Case 3: SM-WM-SC-VE 
(graph c). The graph (d) is the temperature at the junction of SC and VE at each 
case over time.  
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4.3.4 Selective thermal skin ablation 
Guided by the energy characterization of the MSA system, the removal of stratum 
corneum was performed and visualized in pig cadaver skin, as described in section 4.3.2. 
As hypothesized, the energy impact generated by the MSA system could remove stratum 
corneum selectively (Figure 4.23) in a localized manner by using the windows mask. 
However, deposition of dark material was found on the skin and this is a critical problem 
during the MSA application. When the MSA operation was performed and the 
microchamber was viewed, the metal electrode was not intact (data not shown) indicating 
that the electrode melted by arc discharge. Moreover, considering the result of the 
temperature measurement described in Figure 4.25 and the melting point (around 260oC) 
of the Mylar sheet used as the material of the microchamber, the deposited dark material 
may be the mixture of melted material created by arc discharge, most of which is 
probably Mylar debris.  
As mentioned previously in section 4.3.2, the MSA function is the conversion of 
stored electrical energy in the system to thermal or mechanical energy through arc 
discharge phenomenon, which enables the high speed transformation of the energy. If a 
very hot medium at for example, 1100oC, can be prepared separately and the contact of 
this energy medium and the skin can be mechanically controlled at the high speed, this 
system will also be able to ablate the skin selectively. However, these systems seem to be 
practically impossible and inefficient due to problems such as the length of time that the 
system can maintain the hot medium and the type of material that the system should use 
in order to survive thermal energy. 
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The MSA system in this study relies on rapid generation and extinction of the 
applied energy for the short contact time of the ablation energy. It is suggested that the 
energy transformation into energy impact is feasible by arc discharge phenomenon as a 
result of the measurements performed in this study, but it is not yet clearly explained by 
which mechanisms MSA function occurs; that is, thermal by heat or mechanical by jet. 
Therefore, the solid masking system was designed to study the mechanism of the MSA 
function as well as to resolve the deposition of the unfavorable dark material.  
Tungsten was selected as the material for the solid mask, because it has a high 
melting point necessary for resisting the hot medium and good thermal conductivity for 
transferring thermal energy. The MSA with the solid mask was performed on pig cadaver 
skin samples which were viewed as shown in Figure 4.27. The surface of the untreated 
skin (Figure 4.27 (a)) and the skin ablated by the MSA system (Figure 4.27 (c)) looked 
almost the same and had no significant differences. As expected, neither the dark material 
nor any other debris was found in the pig skin sample ablated by MSA system using the 
solid mask. 
To examine how the MSA system could thermally ablate the skin with the solid 
mask, a hydrophilic compound, sulforhodamine, was applied to the surface of each piece 
skin for 12 hours. After 12 h delivery of sulforhodamine, the untreated skin (Figure 4.27 
(b)) did not show any color change, the MSA ablated skin showed radially decreasing 
intensity of purple color inside the skin (Figure 4.27 (d)). This means that sulforhodamine 
could not diffuse through untreated skin due to the stratum corneum, but it could diffuse 
into the MSA ablated skin, indicating that removal of the skin barrier could be performed 
by thermal energy.  
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To confirm the removal of stratum corneum in the MSA treated skin, cross-sections 
of untreated and ablated skin samples were visualized as histological sample images 
using fluorescence and brightfield microscopy before and after staining with H&E, a 
common skin stain used for histology. The brightfield and fluorescent images (Figure 
4.28 (a) and (b)) of the ablated skin sample show the gradual color change of 
sulforhodamine from the ablated top to the deeper tissue and fluorescence due to the 
diffused sulforhodamine, respectively. Figure 4.28 (c) shows a cross section of the H&E 
stained skin samples which had intact stratum corneum of the untreated skin and which 
lost stratum corneum in ablated skin without epidermis damage.  
According to Figure 4.27 and 4.28, it is suggested that the function of skin ablation 
by the MSA system could be achieved only by thermal energy to allow hydrophilic 
compound to diffuse into the skin. Moreover, the rapid transfer of thermal energy through 
the solid mask could remove stratum corneum selectively as shown in Figure 4.28 (d). 
This implies that thermal ablation is probably the more dominant mechanism over 
mechanical ablation due to the jet ejected from the microchamber. However, when hot 
medium is ejected, thermal energy diverges resulting in the large area of the skin ablation. 
For this, the second windows mask was designed to guide thermal impact for the 
localized and controlled removal of stratum corneum, where the heat released from arc 
discharge is transferred through windows and is blocked by other area of windows mask. 
It was found that MSA function with arc discharge phenomenon could remove 
stratum corneum selectively by the impact of thermal energy. The next step is controlling 
the selective removal of stratum corneum. As discussed before, the localization of the 
skin ablation is important to control the release rate of drug by adjusting the ablated area 
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of the skin. To achieve this, the windows mask was designed to specify the localization 
of the selective removal of stratum corneum as shown in Figure 4.29. In addition to the 
creating localizing effect by holes in the windows mask, the windows mask should hinder 
the penetration of thermal energy from the solid mask, preventing damage to the deeper 
skin tissue as well as keep its integrity against high temperature. These features were 





Figure 4.27 Hydrophilic drug (sulforhodamine) delivery into pig cadaver skin with 
thermal skin ablation system. Top views of (a) the untreated skin and (c) the skin 
treated with thermal ablation system before sulforhodamine delivery. Top views of 




                                     Untreated                                                     Ablated 
 
Figure 4.28 Histological images of untreated (left) and ablated (right) skin samples. 








The localization of selective removal by impact of thermal energy was visualized in 
Figure 4.29 for a system using two masks (solid and windows mask) by the same method 
used to produce the images in Figure 4.27 and 4.28. After the surface of the skin treated 
with the two masks system (Figure 4.29 (a)), no black residue was found similar to 
Figure 4.27 (c).  The delivery of sulforhodamine could be verified by the multiple dark 
pink dots in Figure 4.29 (b), which represents localized removal of stratum corneum. 
From the cross-sectional image of the same skin samples, the diffusion of sulforhodamine 
(Figure 4.29 (c)) and the localized and selective removal of stratum corneum (Figure 4.29 
(d)) were confirmed. Figure 4.29 (d) shows the importance of MSA application; the 
technical significance of the localized and selective removal of stratum corneum by the 
MSA function is the control of the skin ablation in a three dimensional way. The rapid 
impact of thermal energy can enable the removal of the skin along the Z axis and the 
windows mask system control the area of the localization of the skin ablation in the X 
and Y planes. The Z direction of the skin ablation might be controlled by the system 
parameters such as MOSFET pulse width and thermal properties or thickness of material 
used for the solid mask. The X and Y directions of the skin ablation can be determined by 
the design of holes in the windows mask. By using this masking system, it is highly 
probable that thermal skin ablation can be controlled in three dimensions and the 
therapeutic rate of drug diffusing into the body might be successfully controlled by the 










Figure 4.29 The localization of thermal skin ablation. The surface of pig cadaver 
skin (a) after the treatment of thermal ablation system and (b) after 30 min delivery 
of sulforhodamine. (c) The cross-section of the same sample imaged by the overlay 










Figure 4.30 Histological images of H&E stained pig cadaver skin applied by arc-
based thermal ablation system with (a) the solid mask and (b) the solid and windows 




4.3.5 Skin permeability and transdermal flux 
We expected that the localized and selective removal of stratum corneum can 
enhance the skin permeability of high molecular weight and hydrophilic biomolecules 
drugs. Even if various parameters are involved in the determination of the release rate of 
drug for the real applications, the flux of drug will be significantly increased by removing 
stratum corneum, which is the rate determining layer in most transdermal patch 
applications. The study of drug release using Franz cell was designed to investigate the 
enhanced effect of the thermal ablation system on transdermal drug delivery in human 
cadaver epidermis and full thickness skin using two different molecular weight 
compounds; sulforhodamine and Texas Red BSA. 
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Figure 4.31 shows the enhanced flux of molecules when human cadaver epidermis 
was applied by the MSA system. For each molecule, thermally ablated epidermis showed 
a dramatically increased flux 1000 fold higher than intact epidermis. This is definitely 
due to the removal of the major skin barrier, stratum corneum. The increased flux in the 
ablated skin in Figure 4.31 could be interpreted as the ablation effect of the MSA system. 
However, this increase of flux was estimated by using solely the epidermis layer, 
therefore it may be different from in vivo using the transdermal patch application. Holes 
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Figure 4.31 Normalized flux of low MW compound (Sulforhodamine) and high MW 
compound (Texas red BSA) through non-ablated (control) and thermally ablated 






Figure 4.32 The surface of (a) intact epidermis and (b) thermally ablated epidermis 
used in Franz cell for the flux measurement shown in Figure 4.31. 
 
 
Next, the permeability coefficient in pseudo-steady-state flux used to characterize 
the skin permeation of drugs 39 was measured to assess the effect of thermal skin ablation 
on the skin permeation of drugs and to compare the diffusion of molecules through intact 





J : flux in pseudo-steady-state flux 
kp : permeability coefficient 




The permeation profile of sulforhodamine and Texas red BSA through each type of 
skin is shown in Figure 4.33. As expected, the non-ablated intact skin did not allow either 
low or high MW drugs to diffuse through it until the end of experiment, so the flux of 
two compounds is zero resulting in very poor skin permeability. The thermally ablated 
skin samples showed a remarkable increase in the flux of each compound, reconfirming 
the effect of the stratum corneum removal on transdermal drug delivery. Similar to the 
skin permeation profile 39, 49 of small size drugs with conventional transdermal patches, 
the flux of the two molecules tested for this study became constant over the application 
time after the specific time, which is considered the lag time. 
While the lag time of the traditional transdermal patch application is related to the 
barrier properties of stratum corneum, the lag time shown in Figure 4.33 is attributed to 
the barrier properties of viable epidermis and/or dermis in thermally ablated skin and 
epidermis stripped skin. However, the vascular structures in the dermis layer during the 
in vivo case will absorb drugs into the body and drive the circulation of drug, rather than 
function as a skin barrier. Thus, the flux profile of molecules through epidermis stripped 
skin in Figure 4.33 might be used to compare the diffusion barrier of the skin thermally 
ablated with the MSA system. 
In Figure 4.33, full thickness skin ablated by MSA for each molecule showed 
constant flux from 6 h to 24 h for sulforhodamine (ANOVA, 95% significance, p=0.28) 
and from 18 h to 48 h for Texas Red BSA (ANOVA, 95% significance, p=0.18). 
Similarly, epidermis stripped full thickness skin also showed the almost constant flux 
from 6 h to 24 h for sulforhodamine (ANOVA, 95% significance, p=0.22) and from 18 h 
to 48 h for Texas Red BSA (ANOVA, 95% significance, p=0.05).  The lag time of 
133 
 
sulforhodamine was 6.0 ± 2.0 (SD) hour for MSA ablated skin and 6.3 ± 1.1 (SD) hour 
for epidermis stripped skin, respectively; and the lag time of Texas Red BSA was 11.7 ± 
4.8 (SD) hour for MSA ablated skin and 12.7 ± 3.0 (SD) hour for epidermis stripped skin, 
respectively. The lag time for each molecule diffused into two different types of skin was 
found to be the same (Students’ t-test, 95% significance, p=0.78 for sulforhodamine and 
p=0.72 for Texas Red BSA). Furthermore, the profile for the cumulative amount per unit 
area for each type of skin after each lag time (12 to 24 h for sulforhodamine and 18 to 48 
h for Texas Red BSA) was almost the same. (two-way ANOVA, 95% significance, 
p=0.27 for sulforhodamine and p=0.48 for Texas Red BSA). 
When constant flux was achieved, the permeability coefficient of sulforhodamine 
and Texas Red BSA was calculated as 3.13 ± 0.88 (SD) ×10-2 and 3.63 ± 0.82 (SD) ×10-3 
cm/h for thermally ablated skin, respectively. As expected, when the epidermis stripped 
full skin was tested to evaluate the permeation profile of each compound, the 
permeability coefficient value (3.13 ± 1.3 (SD) ×10-2 cm/h for sulforhodamine and 2.84 ± 
0.47 (SD) ×10-3 cm/h for Texas Red BSA) was almost the same as the value measured 
using the thermally ablated full skin (Students’ t-test, 95% significance, p=0.99 for 
sulforhodamine and p=0.1 for Texas Red BSA).  
From the result of Figure 4.33, the permeability coefficient for each molecule in 
both MSA ablated skin and epidermis stripped skin is the same, suggesting that the 
difference of two skin, epidermis layer, did not affect the permeation of molecules 
significantly and the lag time was solely attributed to dermis layer, which is the rate 
controlling layer for the diffusion of molecule through each skin in this experiment. 
These findings may be extrapolated to show two things. (1) It is likely that once stratum 
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corneum is removed, the flux of molecules is less irrelevant to the area of the removed 
stratum corneum. Thus, localized multiple ablation sites would bring the same 
transdermal delivery effect as a single large ablation site equaling the same area. 
Furthermore, a design with multiple ablation sites will help skin healing after the ablation. 
(2) As described 39, the dermis layer drives the absorption of drug in the in vivo case due 
to vascular structure present. Therefore, since the dermis layer was the rate-controlling 
layer in the in-vitro experiment, the MSA function will enhance the drug diffusion 
probably without any hindrance effect from dermis layer.  
Figure 4.34 and 4.35 show fluorescent cross-section images of each piece of full 
thickness skin through which the two model drugs diffused respectively. While thermally 
ablated and epidermis stripped skin showed a gradual increase in fluorescence intensity 
over time, intact skin showed no fluorescence in the skin, confirming the findings from 
Figure 4.33. Although the permeability coefficient of each drug has a similar value for 
both thermally ablated skin by the MSA system and epidermis stripped skin, the intensity 
of fluorescence of each image in the two groups shown in Figure 4.34 and 4.35 appears to 
be different. The intensity discrepancy is due to the difference in the diffusion area of 
each piece of skin. The applied area through epidermis stripped skin was 20 fold higher 
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Figure 4.33 The permeation profile of (a) low molecular weight compound, 
sulforhodamine and (b) high molecular weight compound, Texas Red BSA with 















5.1 Dissolving microneedles 
The dissolving microneedles designed in this study may enable (1) bolus and 
sustained delivery of drugs into the skin, (2) self-administration of drugs that would 
otherwise require a hypodermic needle and (3) elimination of dangers associated with 
improper needle disposal and intentional re-use, especially in the developing world.  
Previous studies that have developed microneedles that dissolve or degrade in the 
skin have either melted polymer into a mold at high temperature 124, 125, which can 
damage sensitive biomolecules, or have hand assembled individual needles of millimeter 
dimensions 126, which is a poorly controlled and non-manufacturable process. This study 
has developed a well-controlled, reproducible process for fabrication under gentle 
conditions that designed to maintain protein integrity.  
Selecting the right microneedle geometry and material were important to making 
functional dissolving microneedles. Most water-soluble materials are mechanically 
weaker than non-dissolving materials like metal or silicon. Given the many constraints, 
including water solubility, mechanical strength, processability, and established safety, we 
selected naturally occurring polysaccharides, i.e., CMC and amylopectin. However, 
polysaccharide microneedles having the same dimensions previously designed for metal 
and silicon microneedles were not strong enough. Therefore, mechanical strength was 
increased by reducing the microneedle aspect ratio, which permitted insertion into skin, 
although complete insertion of the microneedle shaft was not achieved. For adding the 
faster dissolution property, disaccharide, for example, trehalose was mixed with CMC for 
27, 127Another feature of our dissolving microneedles is that the backing membrane to 
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which microneedles are attached has been used, for the first time, as a drug reservoir for 
sustained drug delivery over many days. Previous approaches have encapsulated drug 
only within microneedle shafts 124-126 or, alternatively, coated drug onto the surface of 
microneedle shafts 29, 128. These approaches have been limited to small (e.g., microgram) 
drug doses due to the inherently small volume and surface area of microneedles. Our use 
of the backing membrane as a drug reservoir may increase total doses to milligrams.  
Previous studies have also pretreated skin by piercing it with microneedles and then 
applying a topical formulation or patch to deliver drug through the permeabilized skin 27, 
127. This two-step process may be cumbersome for patients and susceptible to mistakes. 
In this study, we mimicked this scenario, but accomplished it as a one-step process by 
using dissolving microneedles, which did not need to be removed after piercing the skin 
and were integrated onto the surface of a backing layer that served functionally as a 
transdermal patch. By controlling microneedle patch design, release kinetics was 
controlled over times ranging from minutes to days. Further design and formulation 
changes should be able to achieve a variety of different bolus and sustained release 
profiles.  
Release from the backing layer reservoir probably occurs by a set of interacting 
phenomena. First, microneedles insert into the skin and dissolve, which creates channels 
for drug transport into skin and for interstitial fluid transport out of skin. Although drug 
may diffuse through a dry backing layer, drug diffusion should be enhanced by hydrating 
the backing layer with interstitial fluid from skin. Consistent with this expectation, the 
backing layer of microneedle patches was seen to swell and soften over time during 
sustained release delivery experiments presented in Figure 4.8. This suggests that the 
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patch backing layer swelled by imbibing interstitial fluid from skin through channels 
created by microneedles. This observation is not only relevant to understanding drug 
delivery mechanisms, but also suggests uses to extract interstitial fluid for diagnostic 
applications, such as measuring glucose concentration in diabetics or monitoring 
industrial toxins in at-risk populations.  
We found that a model enzyme, lysozyme, was encapsulated in CMC microneedles 
without the significant change of its integrity even after two months storage at room 
temperature (Figure 4.9). The long-tem stability of biotherapeutics may be an important 
factor to consider due to the time associated with the distribution process of them from 
the manufacturer to individual patients. Contrary to small molecule drugs based on 
chemicals with the long expiration date, biotherapeutics are very sensitive. The protein 
stability seen in this study may be explained by the limited molecular mobility in the 
solid state that is known to enhance protein stability 32. Additional studies are needed to 
determine if other proteins are similarly stable.  
Based on all of these findings in vitro, additional studies were continued to assess 
in vivo performance of dissolving microneedles using hairless rats. For this, human 
growth hormone (hGH) was selected as a model drug because it should be administered 
multiple times a week, the formulated hGH for the injection should be kept under the 
specific protocol to maintain its integrity, and most patients are children who often have 
fear of hypodermic needles 9. 
Transdermal drug delivery with dissolving microneedles is achieved for the time 
between the breakage and the resealing of stratum corneum. After the skin is resealed, 
drug will not be able to diffuse into the skin. Thus, the skin resealing time should be first 
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assessed with dissolving microneedles to check the available administration time. In case 
of the insertion of CMC microneedles, the skin was resealed slowly, suggesting that 
CMC dissolving microneedles can deliver hGH for bolus without the time limit given by 
the skin resealing process. However, the usage of CMC microneedles for the sustained 
release application, the skin reaction like irritation should be fully evaluated and needs to 
be addressed, even though microneedles were fabricated using materials found in other 
FDA-approved formulations. 
Next to the fabrication of dissolving microneedles, the most critical issue of 
dissolving microneedles application is whether to maintain the integrity of drug 
encapsulated within microneedles. The integrity of biopharmaceuticals should be 
examined to determine the dose of drug in the system for the therapeutic amount of drug, 
bioavailability, and the storage period, all of which are cost-affecting considerations. 
hGH encapsulated in CMC microneedles did not lose its integrity, suggesting that the 
fabrication processes of CMC dissolving microneedles are compatible with the 
formulation of biopharmaceuticals, but hGH stored for 3 and 15 months after the 
fabrication without controlling the storage condition showed 15% (Nb2 cell proliferation 
study) and 40% (pharmacokinetics study) decreased activity, respectively. This means 
that hGH started degrading over time after the fabrication. To improve the quality of 
hGH encapsulated within microneedles for the long period, the specific protocol like the 
vacuum packaging or refrigerated storage might be needed. 
The bolus hGH in vivo delivery experiment suggests several meaningful messages. 
First of all, the fabrication processes of hGH dissolving microneedles are compatible with 
the formulation of hGH to make the solid form which is the preferred for the storage. 
142 
 
Although most biopharmaceuticals are delivered with the injection of the liquid 
formulation, they are usually formulated as the solid form (lyophilized) and then 
reconstituted before the injection because biomolecules in the liquid formulation can be 
easily degraded during the storage. Thus, dissolving microneedles are a kind of hybrid 
platform combining the solid and the liquid formulation to take advantages of each 
formulation; the better stability and the easier administration.  
We found out that carboxymethylcellulose, CMC is good material as microneedles 
matrix for the insertion function of microneedles and the encapsulation of hGH. However, 
according to the results of Figure 4.18 (in vitro release) and 4.14 (in vivo release), the 
dissolution of microneedles matrix can be enhanced with the mixture made out of 
material having the better solubility. This was supported by two findings; the same 
bioavailability of the reconstituted hGH (106 ± 6 %) to the unprocessed hGH (100 ± 8 %) 
and the higher bioavailability of hGH in CMC/trehalose (71 ± 7 %) than hGH in CMC 
only (13 ± 3 %). This would suggest that dissolving microneedles could be fabricated 
with the mixture matrix to add the specific function to the microneedles system. In this 
study, disaccharide, trehalose was mixed to provide the better dissolution of microneedles 
matrix and the faster release of hGH and thereby to increase the bioavailability of hGH. 
 
5.2 Micro skin ablation 
The ablation of stratum corneum is conceptually a very simple and straightforward 
method to increase the flux of molecules through the skin into the body. Previous 
ablation methods were impractical with the subjective manner of the ablation 24 due to 
longer operation times that can cause unfavorable effects 21, such as deeper skin damage. 
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The key point of the skin ablation method is the selective removal of the skin barrier, 
stratum corneum, without any damage of the deeper skin tissue. In this study, the micro 
skin ablation (MSA) system was developed to achieve the localized and selective 
removal of stratum corneum using the impact of the energy generated by arc discharge 
phenomenon. Because the generation and extinction of arc discharge was completed 
within around 100 µs, the ablation of stratum corneum is expected to be much faster than 
other ablation techniques 21, 91 that are performed between 1 ms and 10 ms.  
The microchamber where arc discharge occurs was fabricated by laser machining 
and lamination technologies. These fabrication processes can enable mass production 
reducing fabrication cost of the MSA system. This system will be more practical if the 
power supplying system could be minimized enough to provide the electrical energy for 
the generation of arc discharge. 
The energy released from arc discharge is converted into mechanical and thermal 
energy. Both mechanical and thermal effects could contribute to the ablation mechanism, 
but it was found that thermal ablation is the dominant mechanism of MSA system by 
using the two mask system; the solid mask to block mechanical effect and the windows 
mask to guide the impact of thermal energy. The thermal energy is transferred through 
the metal solid mask to the stratum corneum, which is heated very rapidly and causes the 
lipid layers encompassing corneocytes to be melted resulting in the disintegration or 
decomposition 123 of stratum corneum.  
In previous technologies 21, 91 using thermal energy, the heating elements fabricated 
to generate thermal energy contact the skin directly. Thus, heating elements should be 
designed to optimize the way in which the thermal energy is generated rapidly, and the 
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contact of heating elements to the skin might be dependent on the design of heating 
elements. Contrary to these methods, the MSA function is composed two distinct steps; 
(1) the generation of thermal energy and (2) the control of the skin ablation. The 
significance of this mechanism is that the duration and amount of thermal energy will 
control the depth of the skin ablation and the masking system can control the size of the 
skin ablation. Therefore, the MSA system may achieve three-dimensionally controlled 
ablation of stratum corneum.  
After localized and selective removal of stratum corneum, two molecules 
representing hydrophilic drugs and biotherapeutic were delivered to assess the effects of 
the MSA system on transdermal drug delivery. The intact skin had an extremely long lag 
time meaning no diffusion of molecules through the skin, while the skin ablated with the 
MSA showed significantly increased permeability to each molecule. Moreover, the 
permeation profiles of MSA ablated skin and epidermis stripped skin, as shown in Figure 
4.33, suggested that the dermis became the rate determining layer after stratum corneum 
ablation. Because the dermis does not play the role of the skin barrier for transdermal 
drug delivery in the in-vivo situation, the technical meaning of Figure 4.33 is that MSA 
ablated skin has an extremely small practical barrier of the skin, the amount of drug 
diffusion will be controlled mostly by the area of the ablated skin, and the geometry of 





This study presents (1) transdermal delivery of human growth hormone (hGH) with 
dissolving microneedles and (2) a new method of thermal ablation based on arc discharge. 
The dissolving microneedles system was developed with a design involving fabrication 
under mild conditions that may be suitable for protein delivery and amenable to mass 
production. It was realized by selecting FDA-approved polysaccharides and modifying a 
casting method with centrifugation. By using a low aspect ratio and pyramidal geometry, 
dissolving microneedles were formulated to have sufficient mechanical strength to insert 
into skin. By selectively loading microneedle shafts, microneedle patches provided bolus 
release of a model drug upon the dissolution of the microneedle matrix inside skin. By 
loading the backing layer, microneedle patches provided sustained release probably due 
to drug diffusion and swelling of the backing layer over time. Model drug release rate 
was controlled by altering microneedle formulation. A model protein (i.e., lysozyme) 
maintained structural and functional integrity after encapsulation and release from 
dissolving microneedles, even after two months storage at room temperature. Overall, 
dissolving microneedles may be useful as a method for patients to self-administer drugs 
without the pain or hazards of hypodermic needles. 
Guided by the development of dissolving microneedles, transdermal delivery of 
hGH was demonstrated with the fabrication of dissolving microneedles encapsulating 
hGH. By using SDS-PAGE and Nb2 cell proliferation to examine the integrity of the 
processed hGH, it was found that the integrity of hGH encapsulated in microneedles was 
not damaged during the fabrication processes, but it was partially degraded 
(approximately 15%) after three months storage at room temperature. By measuring the 
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impedance of the skin inserted with CMC dissolving microneedles, CMC microneedles 
was determined to be possibly applied for at least 1 day. From the pharmacokinetics of 
hGH administered into hairless rats with microneedles or a hypodermic needle, the 
bioavailability of hGH dissolving microneedles was determined up to 71 % with the 
comparison of the subcutaneously injected hGH, but the minimum 17 % of the total 
amount of hGH remained in microneedles because of the imperfect insertion with the 
viscoelastic properties of skin. 
The micro skin ablation (MSA) system was designed for the localized and selective 
removal of stratum corneum on the basis of the impact of energy on skin with arc 
discharge phenomenon. The microchamber for generating arc discharge was fabricated in 
a way that can enable the mass production of the device. The dominant mechanism of 
MSA function was thought to be based on thermal effect rather than mechanical effect. 
The thermal energy from arc discharge was impacted on the skin surface for around 100 
µs with the guidance of the masking system which enabled localized and selective 
removal of stratum corneum, implying the possibility of three-dimensionally controlled 
skin ablation. The skin ablated by the MSA system showed significantly increased skin 
permeability to two molecules, sulforhodamine and Texas Red BSA, suggesting the 




Based on the results of this thesis, I would recommend three further studies. 
Regarding the bioavailability of drug delivered with the dissolving microneedles system, 
the geometry of dissolving microneedles may be modified to have the more perfect 
delivery of drug into the body to reduce the amount of drug remaining in the system. The 
geometry of dissolving microneedles was designed to have a low aspect ratio, thus 
providing better mechanical properties for the insertion of these microneedles, which 
were made of the mechanically poor material. If the geometry of microneedles is 
designed to give better good mechanical property and the improved delivery of drug into 
the body without loss, it will probably result in higher bioavailability of drug.  
In addition, the reason for the missing portion of the total amount of drug 
encapsulated within microneedles was figured out to be the slower absorbing rate of drug 
from the microneedles matrix to the circulation system, by comparing the administration 
of the reconstituted drug using the injection. To prove this, multiple microneedles 
systems with the same total amount of drug as that in a single microneedle system can be 
used to examine the effect of absorbing rate from the system into the body on the 
bioavailability. 
The MSA system showed localized and selective removal of stratum corneum after 
the impact of thermal energy. By using human cadaver skin, the in vitro permeation 
profile of the MSA treated skin showed remarkably increased delivery of molecules 
across skin. If the entire system, including the microchamber and the external power 
supplying system, is fabricated with the integrated and portable size used for in vivo 
experiments, the actual skin permeability of biopharmaceuticals delivered by this method 
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can be estimated. Also, optimization of parameters related to the masking system and the 
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